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Various intrinsic and external factors are constantly attacking the cells causing damage to DNA and 
to other cellular structures. Cells in turn, have evolved with different kinds of mechanisms to 
protect against the attacks and to repair the damage. Ultraviolet radiation (UVR) is one of the major 
environmental genotoxic carcinogens that causes DNA lesions. At present, 1-10% of radiation 
reaching the earth is UVB, and over 90% is UVA. However, the proportion of the shorter 
wavelengths has been in increase due to the depletion of ozone layer. UVR induces inflammation, 
mutations, immunosuppression, accelerated aging of the skin and skin cancers. Epidermis is the 
outermost layer of the skin consisting mostly of keratinocytes, whose primary function is to protect 
the skin against e.g. UV radiation.  
LIM domain proteins are a group of proteins involved in regulation of cell growth, damage 
signalling, cell fate determination and signal transduction. Despite their two zinc fingers, LIM 
domains do not bind to DNA, but rather mediate protein-protein interactions and function as 
modular protein binding interfaces. LIM domain proteins may operate through interactions with 
other proteins by acting as adaptors, competitors, autoinhibitors or localizers.  
Csrp1 was initially identified as a UVR-regulated transcript by using expression profiling (Gentile 
et al., 2003). We have further studied regulation and function of CRP1, a representative of cysteine 
rich protein- family consisting of two LIM domains, and find that CRP1 is increased by UVB in 
primary human keratinocytes and by UVC in normal human skin fibroblasts. Ectopic expression of 
CRP1 protected the cells against UVC and provided a survival advantage for the cells, whereas 
silencing of CRP1 rendered the cells more photosensitive. Furthermore, in keratinocytes CRP1 was 
cleaved by caspases preceding apoptosis. Actinic keratosis (AK) is a premalignant lesion in skin 
caused by excess exposure to sunlight and sunburn which may lead to formation of cutaneous 
squamous cell carcinoma (SCC). The expression of CRP1 was increased in basal keratinocytes of 
AK patient specimens suggesting that CRP1 may be increased by constant exposure to UVR and 
may provide survival advantage for the cells also in vivo. In SCC, CRP1 was only expressed in 
tumor surrounding fibroblasts. Moreover, we found that ectopic expression of CRP1 suppresses cell 
proliferation. 
Transforming growth factor  (TGF) is a multifunctional cytokine that regulates several functions 
in cell including growth, apoptosis and differentiation, and plays important role in pathological 
disorders like tumorigenesis and fibrosis. We found that TGF-signaling pathway regulates CRP1 
at protein, but not at transcriptional level. The regulation appeared biphasic, given that CRP1 levels 
were first rapidly increased within one hour followed by a decrease and a sustained increase then 
ensued a few hours later and was stable for a few days. The increase was mediated both through 
Smad and non-Smad signalling pathways involving MAPK/p38. Furthermore, we found that CRP1 
increase by TGF was associated with myofibroblast differentiation, and that CRP1 was 
significantly more expressed in idiopathic pulmonary fibrosis (IPF) patient samples as compared to 
normal lung specimens. As CRP1 is associated with actin cytoskeleton, we also found that CRP1 is 






TABLE OF CONTENTS 
 
ABSTRACT ...................................................................................................................................................... 3 
TABLE OF CONTENTS .................................................................................................................................. 4 
LIST OF ORIGINAL PUBLICATIONS .......................................................................................................... 7 
ABBREVIATIONS ........................................................................................................................................... 8 
REVIEW OF THE LITERATURE ................................................................................................................. 10 
CANCER REPRESENTS DEREGULATION OF NORMAL CELLULAR FUNCTIONS ...................... 10 
CELLULAR STRESS ................................................................................................................................. 10 
Ultraviolet radiation (UVR) .................................................................................................................... 11 
UVR induced DNA damage ..................................................................................................................... 11 
UVR induced damage in the cell ............................................................................................................. 13 
Cellular responses to UV- induced damage ............................................................................................ 13 
STRUCTURE OF THE SKIN ..................................................................................................................... 15 
UV-RELATED SKIN DISEASES .............................................................................................................. 16 
Actinic keratosis ...................................................................................................................................... 16 
Cutaneous squamous cell carcinoma ...................................................................................................... 17 
TRANSFORMING GROWTH FACTOR  (TGF) ................................................................................. 17 
TGF signaling pathway ......................................................................................................................... 18 
Non-Smad pathways ................................................................................................................................ 20 
TGF in cancer progression ................................................................................................................... 20 
TGF in epithelial-mesenchymal transdifferentiation ............................................................................ 21 
Myofibroblasts in pathological conditions (in fibrotic diseases and in tumor progression) ................... 22 
Idiopathic pulmonary fibrosis (IPF) ........................................................................................................ 23 
LIM- DOMAIN PROTEINS ....................................................................................................................... 24 
LIM domain proteins in actin cytoskeleton ............................................................................................. 26 
LIM domain proteins in growth and tumorigenesis ................................................................................ 27 
LIM domain proteins in cellular stress and fate decisions ...................................................................... 28 
LIM domain proteins in TGF-signaling pathway ................................................................................. 31 
THE FAMILY OF CYSTEINE RICH PROTEINS .................................................................................... 31 
Csrp1/ CRP1 ............................................................................................................................................ 32 
Regulation of CRP1 expression ............................................................................................................... 32 
Function of CRP1 .................................................................................................................................... 33 
Csrp2/ CRP2 ............................................................................................................................................ 34 
Csrp3/ CRP3/ MLP .................................................................................................................................. 34 
 5 
AIMS OF THE STUDY .................................................................................................................................. 37 
MATERIALS AND METHODS .................................................................................................................... 38 
MATERIALS .............................................................................................................................................. 38 
Cell lines .................................................................................................................................................. 38 
Antibodies ................................................................................................................................................ 38 
Plasmids .................................................................................................................................................. 38 
Small molecule inhibitors ........................................................................................................................ 39 
Growth factors ......................................................................................................................................... 39 
Tissue samples ......................................................................................................................................... 39 
METHODS .................................................................................................................................................. 39 
Preparation of cellular extracts and immunoblotting (I, II, III) .............................................................. 39 
Immunofluorescence (I, II, III) ................................................................................................................ 39 
Northern blotting (I) ................................................................................................................................ 40 
Flow cytometry (I) ................................................................................................................................... 40 
Immunohistochemistry (II, III) ................................................................................................................ 40 
Quantitative PCR (III) ............................................................................................................................. 41 
Collagen contractility (III) ...................................................................................................................... 41 
Transfection (I, II, III) ............................................................................................................................. 41 
Measurement of the metabolic activity (I) ............................................................................................... 41 
Silencing by using lentiviral shRNA vectors (I, III) ................................................................................. 41 
SiRNA (III) ............................................................................................................................................... 42 
RESULTS AND DISCUSSION ...................................................................................................................... 43 
LOCALIZATION OF CRP1 TO THE ACTIN CYTOSKELETON (I, III) ............................................... 43 
EFFECTS OF CRP1 ON CELL PROLIFERATION (I, unpublished data) ................................................ 45 
REGULATION OF CRP1 BY UV RADIATION (I, II) ............................................................................. 47 
CRP1 IN SKIN DISEASES (II) .................................................................................................................. 49 
REGULATION OF CRP1 BY TGF SIGNALING PATHWAY (III) ...................................................... 49 
CRP1 IN MYOFIBROBLAST DIFFERENTIATION (I, II, III) AND IN CONTRACTILITY (III) ........ 51 
CRP1 IN IDIOPATHIC PULMONARY FIBROSIS (III) AND IN CANCER- ASSOCIATED 
FIBROBLASTS (II) .................................................................................................................................... 52 
CONCLUSIONS ............................................................................................................................................. 54 
ACKNOWLEDGEMENTS ............................................................................................................................ 55 



















LIST OF ORIGINAL PUBLICATIONS 
 
This thesis is based on the following original publications, which are referred to in the text by their 
Roman numerals. 
 
I. Latonen L*, Järvinen PM*, Laiho M. (2008) Cytoskeleton-interacting LIM-domain protein 
CRP1 suppresses cell proliferation and protects from stress-induced cell death. Exp Cell Res. 
314:738-47 (* These authors equally contributed to this study) 
 
 
II. Latonen L, Järvinen PM, Suomela S, Syrjäkari H, Saarialho-Kere U, Laiho M. (2010) 
Cysteine-rich protein 1 is regulated by UV in human keratinocytes. Photodermatol 
Photoimmunol Photomed. 26:70-7  
 
III. Järvinen PM, Myllärniemi M, Liu H, Moore HM, Leppäranta O, Salmenkivi K, Koli K, 
Latonen L, Band A, Laiho M. (2011) Cysteine-rich protein 1 is regulated by transforming 






ABLIM           actin-binding LIM  
AK                  actinic keratosis  
ALP                alkaline phosphatase 
AP-1               activator protein 1 
ATD               actin-target domain 
ATR               ATM-related 
BCC               basal cell carcinoma 
BMP               bone morphogenetic protein 
CAF                cancer associated fibroblast       
CARP-1          cell cycle and apoptosis regulator protein-1  
CDK               cyclin-dependent kinase 
CDKI              cyclin-dependent kinase inhibitor 
CHK1             CSK-homologous kinase 1 
CK1              casein kinase 1 
CPD                cyclobutane pyrimidine dimers 
CRIP               cysteine-rich intestinal protein 
CRP                cysteine rich protein 
ECM               extra-cellular matrix 
EMT               epithelial-mesenchymal transition 
EPLIN            epithelial protein lost in neoplasm 
ER                  estrogen receptor 
ERK                extra cellular signal-regulated kinase 
FA                  focal adhesion 
FGF                fibroblast growth factor 
FHL                four and half LIM domains 
βGAL             β galactosidase 
GDF                growth and differentiation factor 
GAPDH          glyceraldehyde 3-phosphate dehydrogenase 
HDAC            histone deacetylase  
HGF                hepatocyte growth factor 
Hic-5/ARA55 hydrogen peroxide-inducible gene/ androgen receptor associated protein 55 
HIPK2            homeobox-interacting protein kinase 2 
IL-13               interleukin 13 
IPF                  idiopathic pulmonary fibrosis 
JAM                junctional adhesion molecule 
JNK                c-JUN N-terminal kinase 
LAP                latent associated protein 
LASP              LIM and SH3 protein  
LIM                Lin11, Isl-1 & Mec-3 
LIMD1            LIM domain-containing protein 1 
LIMK              LIM kinase 
LMO               LIM-only 
LOH                loss of heterozygosity 
LTBP              latent transforming growth factor beta-binding protein 
MAPK            mitogen activated protein kinase 
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MDM2            murine double-minute 2  
MEKK            mammalian mitogen-activated protein kinase kinase  
MICAL           molecule interacting with casl 
MLP               muscle LIM protein 
MMP              matrix metalloproteinase 
MRF               muscle regulatory factor 
N-Cor              nuclear receptor corepressor 
NEDD4-2       neural precursor cell expressed, developmentally down-regulated  
NER                nucleotide excision repair  
NHEK             normal human epidermal keratinocyte 
NOX-4            NADPH oxidase 4 
P300/CBP       p300 / CREB-Binding Protein 
PBS                 phosphate buffered saline 
PDLIM            PDZ and LIM domain 
PDGF              platelet derived growth factor 
PI3K                phosphatidylinositol 3-kinase 
PINCH            particularly interesting new cysteine- and histidine-rich protein 
PKC                protein kinase C 
PPAR-           peroxisome proliferator-activated receptor  
PPM1A           protein phosphatase 1 
ROCK            Rho kinase       
ROS                reactive oxygen species 
SARA             smad anchor for receptor activation 
SCC                squamous cell carcinoma 
SDF                stromal derived factor 
SH3                SRC Homology 3 Domain 
SKI                 sloan-kettering institute 
αSMA            α smooth muscle actin 
SMURF         smad ubiquitin ligase 
SNON            ski-novel protein 
SP-C               surfactant associated protein C 
SRF                serum responsive factor 
TAK               transforming growth factor-β-activated kinase 
TGFβ              transforming growth factor 
TGFBR           transforming growth factor receptor 
TERC             telomerase RNA template 
TERT             telomerase reverse transcriptase 
TLP                thymus LIM protein 
TMEPAI        transmembrane TGF-beta-inducible protein 
TNF             tumor necrosis factor 
TRAF             tumor necrosis factor receptor-associated factor 
TRAIL           TNF-related apoptosis-inducing ligand 
UV(R)            ultraviolet (radiation) 
VASP             vasodilator-stimulated phosphoprotein  
VHP               villin headpiece domain             
XP                  xeroderma pigmentosum 
ZO                  zona occludens 
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REVIEW OF THE LITERATURE 
 
CANCER REPRESENTS DEREGULATION OF NORMAL CELLULAR FUNCTIONS  
Cancer is one of the prevalent causes of deaths in western countries and is a disease of deregulated 
cell growth. Tumours acquire traits that have been called hallmarks of cancer. These include 
sustained proliferative signaling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis and activating invasion and metastases. Underlying 
these hallmarks is the genomic instability that enables the tumors to acquire these properties 
(Hanahan and Weinberg, 2011). 
Same genes that are required to sustain normal cell homeostasis such as cell proliferation, death, 
angiogenesis and migration, are mutated and dysfunctional in cancers. For example the alterations 
in genes functioning in DNA damage recognition and repair may lead to the survival of cells with 
genomic alterations and therefore increase the chance of genomic instability and cancer 
development (Kastan and Bartek, 2004). Genes affected in tumorigenesis have frequently properties 
of oncogenes or tumor suppressors. Oncogenes are mutated, expressed in excess or otherwise 
activated and they have the ability to promote malignant tumor growth, whereas tumor suppressors 
repress the growth or other traits of the tumors, and are commonly lost or their function is 
attenuated in cancers.  
 
CELLULAR STRESS 
Various intrinsic and external factors are constantly attacking the cells causing damage to DNA and 
to other cellular structures, and cells in turn have evolved with different kinds of mechanisms to 
protect against the attacks and to repair the damage. Cells are targets for several different types of 
stresses including ionizing radiation (IR), ultraviolet radiation (UVR), viruses, mechanical stress, 
replication errors, heat, free oxygen radicals and hypoxia.  
It is important that during cell division DNA is properly replicated and divided without errors so 
that daughter cells carry the exact copy of DNA of the parental cell. During cell division, cascade of 
molecules will ensure that DNA is replicated without errors. These are called DNA damage 
checkpoints (Fig. 1). Unrepaired lesions may lead to the formation of cancer.    
DNA damage checkpoints occur during the cell cycle in G1 phase in restriction point (R), S-phase 
and between G2/M-phases. Proteins that are involved in DNA damage checkpoints can be divided 
into three groups: sensors, transducers and effectors. Sensors will first recognize the damage and 
signal it to the checkpoint cascade. Signal transducers are often protein kinases and their function is 
to amplify the signal by phosphorylating downstream protein targets, which are called effector 
proteins. DNA damage- induced modifications of effector proteins will then lead to the arrest in cell 
cycle progression, as damaged cell needs to halt the cell cycle to repair the damages before cell 
division continues. If the damage is unrepairable, cell undergoes apoptosis (Kastan and Bartek, 





Figure 1. DNA damage checkpoints. Cell cycle consists of four phases G1, S, G2 and M phase, and is driven by 
different complexes formed between cyclin (box) and cyclin-dependent kinases (circles). Cells may withdraw from the 
cycle and enter into G0 phase. DNA damage checkpoints control the integrity in DNA in G1 (R), S and between G2/M 
phases and in M phase (spindle checkpoint).  
 
Ultraviolet radiation (UVR) 
The sun emits UV radiation at three different wavelengths: UVA 320-400 nm, UVB 290-320 nm 
and UVC 200-290 nm (Diffey, 2002). Ozone layer absorbs 97-99% of UVC, and at present 1-10% 
of earth reaching radiation is UVB, and over 90% is UVA. However, the proportion of the shorter 
wavelengths on the earth has been in increase due to the depletion of ozone layer (Norval et al., 
2011). UVR induces inflammation, mutations, immunosuppression, accelerated aging of the skin 
and skin cancers (Halliday, 2005). 
  
UVR induced DNA damage  
To exert its biological effects, UV must first be absorbed by a cellular chromophore, which 
transfers the energy into a biochemical signal. The most common chromophore for UVB is DNA 
(Kulms and Schwarz, 2000).  
UVR is one of the major environmental genotoxic carcinogens that cause DNA damage and may 
lead to the cell death. UVR inflicts several types of lesions on DNA. The most frequent types of 
lesions caused by UVB and UVC are formation of cyclobutane pyrimidine dimers (CPDs), 6-4 
pyrimidine pyrimidone photoproducts (6-4 PP), their Dewar valence photoisomers and DNA strand 
breaks (Rastogi et al., 2010).  
UVA exhibits a poor absorbance to DNA, and it has mainly thought to induce DNA lesions 
indirectly by inducing reactive oxygen species (ROS) and to result in single-strand breaks in DNA 
and in DNA–protein crosslinks (Brenner and Hearing, 2008). However, UVA induces CPD-type 
 12 
mutations in rodents although in lesser extent than UVB or UVC (Pfeifer et al., 2005). A recent 
publication suggests that different types of lesions show wavelength dependency and that CPDs are 
the principal type of lesions induced by sun light (Besaratinia et al., 2011) (Fig. 2). However, UVA 
penetrates the skin deeper than UVB or UVC (Narayanan et al., 2010). 
  
 
Figure 2. Sun emits ultraviolet radiation at three different wavelengths UVA, UVB and UVC, and the energy levels are 
negatively correlated with the wavelength. Ozone layer absorbs most of the UVC, and as UVA does not cause directly 
DNA damage, UVB is the most potent inducer of skin cancer. UVA mainly induces the formation of reactive oxygen 
species, whereas UVB and UVC causes 6-4 photoproducts and CPD type of DNA lesions. CPD= cyclobutane 
pyrimidine dimer, ROS= reactive oxygen species 
 
Given that UVR causes damage in DNA, cells have adapted against the attacks by repairing the 
lesions efficiently. By spreading the signals and orchestrating several signaling pathways, the 
damage is recognized within seconds, and by activation of DNA damage checkpoints, cell delays 
cellular processes until the lesions have been repaired (Kastan and Bartek, 2004). ATR (ATM- and 
Rad3-related) acts as a sensor that recognizes the UVR- induced damage in DNA. ATR is a large 
protein kinase that binds to ssDNA and phosphorylates critical substrates. This event will initiate 
the recruitment of several proteins and protein complexes to ssDNA, and will lead to the activation 
of damage checkpoints. One of the ATR-phosphorylated targets is CHK1, which functions as a 
transducer of the damage signal by phosphorylating effector protein targets downstream (Bartek and 
Lukas, 2003). CHK1 targets CDC25A phosphatase (activator of the cyclin E/(A)/CDK2 kinase) for 
proteasomal degradation, which rapidly delays G1/S transition (Mailand et al., 2000). The 
phosphorylation of transcription factor p53 is required for sustained G1 arrest by activating CDK 
inhibitor p21CIP1/WAF1. p53 is a key factor in UV-induced cellular stress response, as it halts cell 
cycle progression until damage has been repaired or provokes the cells to undergo apoptosis in case 
the damage is too severe to be repaired. TP53 is one the most commonly mutated genes in human 
cancers (Kastan and Bartek, 2004). Furthermore, altogether 570 phosphorylated protein targets for 
UV-induced ATM/ATR have been identified (Stokes et al., 2007).   
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Different mechanisms have evolved to repair DNA lesions caused by UVR. These include 
photodamage reversing enzymes (photolyases), base excision repair, nucleotide excision repair 
(NER) and mismatch repair pathways. Since UVR mainly induces pyrimidine dimer-type of 
mutations, NER is the main repair system in UVR-induced DNA damages (Rastogi et al., 2010). 
NER involves damage recognition, local opening of the dsDNA around the lesion, dual incision of 
the damaged DNA strand, gap repair synthesis, and ligation of the strand. Human genetic disorder 
Xeroderma pigmentosum (XP) is a disease with dysfunctional NER, and the carriers of the XP 
mutations are hypersensitive to UV radiation. Seven XP (XPA-XPG) genes required for NER 
mediated DNA repair are defective in XP patients and therefore they lack the ability to repair DNA 
lesions through NER. Hence, they are highly susceptible to all three types of skin cancers 
(Dworaczek and Xiao, 2007).  
UVR also causes damage on TP53 gene (Brash et al., 1991), and five of the eight TP53 hot spot 
mutations carry mutated dipyrimidine nucleotides. These mutations are frequently observed in non-
melanoma skin cancers, and are particularly common also in XP skin tumors.  
 
UVR induced damage in the cell 
DNA is not the only chromophore for UVB. UVB chromophores also include purine and 
pyrimidine bases in RNA, protein aromatic amino acids (tryptophan and tyrosine), urocanic acid, 
melanin, quinones, flavins, 7-dehydrocholesterol, porphyrins and heme groups in catalase and 
oxidase enzymes (Trautinger, 2001). In addition to damage in DNA, UVR also causes injuries in 
cell organelles and actin cytoskeleton reorganization. Organelles such as plasma membrane, 
intercellular contacts, nuclear membranes, Golgi-complex, endoplasmic reticulum, lysosomes, 
cytoskeleton and mitochondria have been reported to suffer from radiation induced injuries 
(Somosy, 2000). Moreover, irradiated mouse lymphoma cells revealed that UVB radiation damaged 
cell structures, resulting in the disappearance of microvilli on the cell surface, destruction of 
mitochondria and vacuolation of cytoplasm (Maekawa et al., 1996).  
In addition, cell morphology and polymerization of filamentous actin are altered (Maekawa et al., 
1996). UV-irradiated Chinese hamster ovary cells showed impaired adherence, disruption of actin 
filaments and stronger F-actin labeling in the center of the cell (Grzanka et al., 2006). Moreover, 
disruption of the cytoskeleton enhances UV-induced apoptosis (Kulms et al., 2002). Actin 
cytoskeletal proteins have also been reported to be degraded in response to UVR, as actin mRNA is 
reduced (Weinreb et al., 2001), and the phosphorylated forms of actin cytoskeleton modulators 
cofilin-1 and destrin are decreased (Hensbergen et al., 2005).  
 
Cellular responses to UV- induced damage 
UVR induces different types of damage to the cells, and the cells may respond either by activating 
cell death or survival pathways. Severity of the damage is highly dependent on the dose of the 
UVR, as lower doses will mostly lead to cell cycle arrest during which lesions are repaired and 
higher doses will lead to apoptosis (Latonen et al., 2001; Gentile et al., 2003). 
Several signal transduction pathways are activated in response to UVR. Transcriptional responses 
have been studied in different cell lines, and the responses vary between the cell types. Responses 
also show wavelength dependency, as different wavelengths induce different types of DNA lesions 
and cellular stress responses (Bode and Dong, 2003). Divergent transcriptional responses were 
detected with doses of UVC either inducing growth arrest or apoptosis in a human skin fibroblast 
cell line (WS-1) (Gentile et al., 2003). Furthermore, UVB induced expression profiles have been 
studied in human keratinocytes (Sesto et al., 2002) and in melanocytes (Valery et al., 2001). In 
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keratinocytes, among the induced transcripts are related to UV-specific inflammatory and stress 
responses, basal transcription, splicing, translation and to proteasome-mediated degradation. On the 
other hand, transcripts related to the metabolism and to adhesion were downregulated (Sesto et al., 
2002). In melanocytes, among the induced transcripts are genes mostly involved in DNA or RNA 
binding, synthesis and modification and also ribosomal proteins, transcription factors, receptors, 
tumor suppressors and oncogenes (Valery et al., 2001). 
Apoptosis of the keratinocytes is the major protective mechanism against damage in the skin in 
response to UV radiation. Through apoptosis the skin will eliminate severely damaged cells and 
decrease the risk of malignant transformation. Various pathways are involved in UV-induced 
apoptosis in response to DNA damage: activation of p53, cell death receptors either directly by UV 
or by death ligands or via mitochondrial damage, and the release of cytochrome C (Kulms and 
Schwarz, 2000) (Fig. 3).  
Death receptors are cell surface receptors that transmit cell death signals initiated by binding of 
their ligands such as Fas, TNFα or TRAIL. Complex formation between death ligands and their 
receptors leads to a receptor conformational change and triggers the imminent initiation of 
apoptosis through activation of caspase proteases 8 and 10. This is called “extrinsic” apoptosis. 
“Intrinsic” apoptosis is initiated by caspase 9 whose activation depends on the release of 
cytochrome c and other pro-apoptotic factors from the mitochondria with the help of the pro-
apoptotic proteins like Bid and Bax. Pro-survival protein Bcl-2 antagonizes these effects by 
inhibiting the release of cytochrome C from mitochondria (van Raam and Salvesen, 2011). 
Interestingly, UVB and UVC induce different apoptotic pathways in human keratinocytes although 
the extent of apoptosis is comparable between these wavelengths (Takasawa et al., 2005). 6-4 PPs 
and CPDs are significantly more frequent following UVC radiation than UVB radiation. Also, the 
release of cytochrome c and Smac/DIABLO and activation of caspase 9 following UVC are greater 
than after UVB. Importantly, caspase 8 activation occurred only in UVB-radiated cells. Thus, UVB 
induces apoptosis through both mitochondrial (intrinsic) and caspase 8 activation (extrinsic) 
pathways, while UVC induces apoptosis only via the intrinsic pathway (Takasawa et al., 2005). 
 
Figure 3. UV-induced cellular pathways. (1) UV causes DNA damage, which activates, among other factors, “the 
guardian of the genome” p53. (2) UV triggers the binding of death ligands to their receptors. This leads to activation of 
caspases. (3) UV may also induce the release of cytochrome c from mitochondria, and lead to caspase-dependent 
apoptosis. (4) UV may also induce apoptosis by causing the clustering of the death receptors even in the absence death 
ligands. Modified from Kulms and Schwarz, 2000. 
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Several proteins have been shown to promote either death or survival of the cells. The induction of 
apoptosis by UV radiation involves the activation of protein kinase C (PKC)-pathways. Cleavage 
and the activation of PKC are important upon UV-induced apoptosis in human keratinocytes, since 
the inactivation of PKC promotes the survival of keratinocytes exposed to UV radiation (D'Costa 
and Denning, 2005). Furthermore, PKC acts as a photosensitizer, as transgenic mice 
overexpressing PKC in the basal epidermal cells and cells of the hair follicle are highly sensitive to 
UVR-induced cutaneous damage and to development of SCC (Aziz et al., 2007). 
Several anti-apoptotic pathways counteract the action of apoptotic pathways, and the end result 
depends on the balance between these two. Akt/protein kinase B (PKB) pathway protects 
keratinocytes from UVR, and in contrast, PKC family is involved in keratinocyte death pathways. 
Activation of PKC and PKC negatively regulate Akt phosphorylation and kinase activity in 
mouse keratinocytes and modify UVC-induced apoptosis in mouse keratinocytes (Li et al., 2006).  
UV-activated signal transduction pathways are primarily mediated by mitogen-activated-protein-
kinases (MAPKs), that include extracellular signal regulated kinases (ERKs), the c-Jun NH2-
terminal kinases (JNKs), and the p38 kinases. UV-induction of MAPKs is highly dependent on 
wavelength, dose and cell type used (Bode and Dong, 2003), and both survival and apoptotic 
functions in UVR- induced cell stress have been suggested for p38. A major effector of the MAP 
kinase pathways is transcription factor AP-1, which is composed of Jun and Fos family proteins. 
Transcription of JUN and FOS genes are induced by a variety of growth factors, cytokines, and 
environmental stimuli, including UVR (Rittie and Fisher, 2002).  
 
STRUCTURE OF THE SKIN 
Skin is composed of three layers: epidermis, dermis and hypodermis. Epidermis is the outermost 
layer consisting of keratinocytes (95%), melanocytes, Langerhans cells and Merkel cells. The 
primary function of keratinocytes is to protect the skin against UV irradiation, pathogens, 
evaporation and heat. Epidermis is composed of five sublayers; stratum corneum, stratum lucidum, 
stratum granulosum, stratum spinosum and stratum basale. The epidermis of the skin is under 
constant renewal, given that undifferentiated basal cells in the stratum basale of the epidermis are 
continuously dividing, and the daughter cells are migrating towards the upper sublayers of the 
epidermis while differentiating into keratinocytes and producing keratin. Finally they start to 
undergo apoptosis and dead cells are then detached from skin surface during a process called 
cornification. Stratum corneum is then the outermost layer composed of large, flat, polyhedral dead 
cells filled with keratin, and this layer is the most important for inhibition of water evaporation.  
Dermis is connected to epidermis by basal membrane, and consists of two layers; papillary and 
reticular region. There are different kinds of specialized organelles in dermis such as hair follicles, 
sweat glands, sebaceous glands, apocrine glands, lymphatic vessels and blood vessels. Collagen, 





Figure 4. The structure of the skin. Two layers of the skin are represented: epidermis and dermis. Epidermis is mostly 
composed of keratinocytes in several layers: stratum corneum, stratum granulosum, stratum lucidum, stratum spinosum 
and stratum basale. Dermis on the other hand is composed of mainly connective tissue, and has several structures, such 
as sweat gland, nerves, glandula sepacea (not shown in this picture) and tactile corpuscle. Adapted from Florida Center 
for Instructional Technology. 
 
UV-RELATED SKIN DISEASES 
Actinic keratosis 
Actinic keratoses (AK) is featured as premalignant lesion on sun-exposed areas of the skin such as 
the face, lower lip, bald scalp, neck, arms and hand. AK is induced especially by UVB and it is 
more common in fair skinned Caucasian population. AK lesions are considered as premalignant, 
since approximately 10% of these lesions will develop into cutaneous squamous cell carcinoma 
(SCC) with a progression time of approximately 2 years (Fuchs and Marmur, 2007).  
Several mutated areas in human genome have been linked with the formation of AK. Mutations in 
TP53 are extremely common in cases of AK, as 75-80 % of Caucasian population, 40 % of Korean 
and 30 % of Japanese will display TP53 mutations (Park et al., 1996). This suggests that p53 
function is needed to protect the cells from UV-induced damage. The expression levels of 
epidermal p53 were compared with AK, adjacent tissue and non-sun exposed tissue. p53 levels 
were significantly elevated in AK and adjacent tissue areas suggesting an association with 
histological evidence of chronic sun damage (Einspahr et al., 1997). Moreover, exposure of human 
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skin transplants to UVB lead to the induction of AK in 14 and SCC in 3 cases out of 18 in 
immunodeficient mice (Nomura et al., 1997). Since mutations in TP53 induced by UV radiation are 
frequently found (Brash et al., 1991), they may allow a selective pressure for the transformed, 
damage-resistant keratinocytes, allowing these cells to clonally expand, form AK, and predispose to 
skin cancer (Ziegler et al., 1994). 
 
Cutaneous squamous cell carcinoma  
UVR induced damage contributes to formation of all types of skin cancers including basal cell 
carcinoma (BCC), cutaneous squamous cell carcinoma (SCC) and cutaneous melanoma. BCC as 
well as SCCs are originated from keratinocytes, whereas melanomas originate from melanocytes. 
BCC is the most common type of skin cancers, but usually resides more local and slowly growing 
than the second most common skin carcinoma SCC. It has been estimated that 2-3 million new 
cases of BCC and SCC arise each year (Narayanan et al., 2010). It has also been estimated that 
about 65 % of the SCC cases are initially AKs (Criscione et al., 2009). Whereas AK is located in 
epidermis, SCC extends more deeply into the dermis.  
Consistent epidemiological evidence for a positive association between UV light exposure and SCC 
risk has been found in 16 of 18 studies (Schmitt et al., 2011). Intact p53 is needed to protect the 
cells from UV-induced damage, and alterations in this gene may cause the formation of skin 
carcinomas. Similarly, all Tp53 knock out mice with chronic exposure to UVB radiation develop 
skin cancer (Li et al., 1998). After 12 weeks of observation five out of ten mice had invasive SCC, 
four SCC in situ and one AK, whereas none of the mice with wild type Tp53 developed skin cancer 
(Li et al., 1998). In humans, TP53 is also mutated in SCC, and about 90% of the invasive SCC 
cases carry a mutation in TP53 (Rass and Reichrath, 2008). Furthermore, both UVA and UVB 
induced skin carcinoma cases have mutated TP53, but the prevalence is fairly different. As about 
60% of the UVB induced skin carcinomas cases had a point mutation in their Tp53 gene in mouse 
model, only 14% of the UVA induced cases had mutated Tp53, suggesting that other gene targets 
are more important in protecting the cells against UVA (van Kranen et al., 1997).  
Immunosuppressed patients develop more aggressive and more numerous SCCs than 
immunocompetent individuals (Bordea et al., 2004). Furthermore, XPC gene required for efficient 
UVR-induced damage repair is consequently inactivated or lost in almost half of SCCs in non-XPC 
patients, suggesting that loss or mutation of XPC may be an early event during skin carcinogenesis 
that provides a selective advantage for initiation and progression of SCC (de Feraudy et al., 2010). 
 
TRANSFORMING GROWTH FACTOR  (TGF) 
TGF belongs to a superfamily consisting of over 40 related proteins including TGF isoforms, 
bone morphogenic protein (BMPs), growth and differentiation factors (GDFs), anti-Müllerian 
hormone (AMH), activin, inhibins and nodal. TGF is a pleiotropic cytokine ubiquitously 
expressed by all cells and tissues in the body and essential for embryogenesis and maintaining the 
tissue homeostasis. To fulfill these important tasks, TGF signaling pathway regulates growth, 
apoptosis, differentiation, adhesion, invasion and extracellular matrix production of the cell 
(Meulmeester and Ten Dijke, 2011). The effect of TGF is context dependent; in epithelial cells it 
may act as a growth inhibitor, whereas in fibroblasts it may stimulate the growth. Dysregulation of 
TGF signaling pathway is involved in pathological disorders like cancer, fibrosis, cardiovascular 
and autoimmune diseases (Rahimi and Leof, 2007).  
Mature TGF ligands (1, 2, 3) are 25 kDa proteins comprising of two polypeptides. TGF is 
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initially synthesized as a 55 kDa precursor molecule, which is dimerized and proteolytically cleaved 
to yield N-terminal propeptide and mature TGF. A small latent TGF complex is then formed 
between a propeptide called as a latent associated protein (LAP) and mature TGF. Usually this 
small latent TGF binds to latent TGF binding protein (LTBP) forming a large latent TGF 
complex, which facilitates the secretion of the complex and directs it to the extracellular matrix. 
Activation of the TGF is tightly controlled, and therefore it is produced and secreted as a latent 
complex preventing the ligand from activation unless certain physiological conditions occur or the 
target cell is reached. Several enzymes or other proteins, such as plasmin, thrombospondin-1, 
integrins, matrix metalloproteinases and calpains release TGF from latent complexes (Hyytiainen 
et al., 2004).  
 
TGF signaling pathway 
TGF ligands are first recognized and bound to the TGF type II receptor. Binding of the ligand 
causes the activation of intracellular serine/threonine kinase domain of type II receptor, which 
phosphorylates the cytoplasmic tail of type I receptor and activates its serine/threonine kinase 
domain. The activated heterotetrameric receptor complex regulates the downstream of Smad and 
non-Smad pathways (Ikushima and Miyazono, 2010) (Fig. 5). Betaglycan (type III receptor) is 
TGF co-receptor that binds to TGF ligands (Lopez-Casillas et al., 1991; Wang et al., 1991).  
The Smad family consists of eight proteins: Smad 2, 3, 4, 7 are regulated by TGF, whereas Smad 
1, 5, 6, 8 are involved in BMP pathway. The Smads can be classified into three different 
fundamental groups; receptor activated- (R-), co- activated- (Co-) and inhibitory (I-) Smads. In 
TGF-signaling pathway Smad2 and Smad3 are receptor activated, Smad4 is co-activated and 
Smad7 has an inhibitory role. The Smad complex that is able to bind chromatin is a trimer 
consisting of two R-Smads and one Co-Smad. The binding of TGF-ligand on the receptor will 
ultimately lead to the phosphorylation of receptor-regulated Smads (2, 3) by type I TGF-receptor, 
after which they form heteromeric complex with Smad4, translocate into the nucleus and regulate 
large transcriptional machinery (Ikushima and Miyazono, 2010).  
TGF regulates the expression of several target genes. To suppress the cell proliferation, TGF  
represses the expression of Myc and vice versa induces the expression of p15 and p21. Moreover, to 
enhance the differentiation, TGF represses Id1, Id2 and Id3 and to promote apoptosis TGF 




Figure 5. TGF-mediated signaling pathways: Smad-signaling and non-Smad signaling pathways. TGF activates type 
II receptor, which in turn phosphorylates type I receptor. Receptor I phosphorylates Smad2/3 which then forms a 
complex with Smad4 and translocates into the nucleus to regulate transcription. In a non-conventional pathway, the 
TGF-signaling is not mediated through Smads, but receptors I and II directly transduce signals to MAPK, Rho 
GTPases, PI3K/Akt and Ras/Erk pathways. Crosstalk between the signaling pathways may occur, for example Smads 
may also activate Rho. 
 
Given that TGF has such diverse effects in the cell, it is crucial that the activation is strictly 
regulated in various ways, including the control of intensity and duration of Smad-signaling. The 
phoshorylation of receptors play a crucial role in signal activation, and therefore dephosphorylation 
plays an important role in deactivation of the receptors. Inhibitory Smad7 is transcriptionally 
induced upon TGF-signaling, and represses TGF-signaling by competing receptor binding with 
R-Smads (Yan and Chen, 2011). Furthermore, several factors have been found to positively or 
negatively regulate the presentation and sequestration of R-Smads to TGF-receptor. Smad anchor 
for receptor activation (SARA) is one of the positive regulators that interacts directly with Smad2/3, 
facilitates their recruitment to the type I receptor and modifies the balance between Smad2 and 
Smad3 (Tsukazaki et al., 1998). On the other hand, TMEPAI negatively regulates R-Smad 
phosphorylation by type I receptor by competing with binding to R-Smads with SARA (Watanabe 
et al., 2010). Phosphorylation of the Smads is a transient event, and several phosphatases are able to 
reverse the phosphorylation. PPM1A was found to dephosphorylate and promote the nuclear export 
of Smad2/3 (Lin et al., 2006), and SCP1, 2, 3 dephosphorylate Smad2/3 at the N-terminus, but not 
in C-terminus resulting in enhancement of TGF signaling (Sapkota et al., 2006).  
TGF signaling is also regulated through proteasomal degradation of Smads and receptors, and 
several specific E3 ligases have been identified to target different factors of the signaling cascade. 
Smad ubiquitin regulator factor 1 and 2 (Smurf1, 2) are E3 ligases that not only target R-Smad and 
type I receptor for degradation, but also facilitate the inhibitory actions of I-Smads. Smurf2 
promotes the degradation of Smad2 (Lin et al., 2000), and both Smurf1 and 2 bind to Smad7 and 
target type I receptor for degradation (Kavsak et al., 2000; Ebisawa et al., 2001). WWP1 and 
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NEDD4-2 both interact with type I receptor via Smad7 (Komuro et al., 2004; Kuratomi et al., 
2005), respectively, and participate in degradation of the receptor. Arkadia is another E3 ligase that 
targets Smad7 for ubiquitination and degradation, and is therefore an important factor amplifying 
TGF signaling (Koinuma et al., 2003). Also deubiquitinases for Smads exists. One of them is 
FAM/USP9x that deubiquitinates Smad4, which is monoubiquitinated at lysine 519 thus preventing 
the interaction with phosphorylated Smad2. As FAM/USP9x is able to revert this ubiquitination, it 
is able to retain active TGF signaling (Dupont et al., 2009). 
Ski and SnoN are the members of the Ski family, and important negative regulators of TGF-
pathway at the transcriptional level. Ski and SnoN regulate TGF-pathway by interacting with 
Smad2/3 and Smad4 and by blocking the ability of the Smad complexes to activate transcription of 
TGF target genes. In addition, Ski or SnoN also prevent the binding of the R-Smads to 
transcriptional co-activator p300/CBP and actively recruit a transcriptional co-repressor complex 
containing N-CoR and HDAC to the targeted promoters (Deheuninck and Luo, 2009).  
 
Non-Smad pathways  
Besides the canonical Smad-pathway, the functional receptor complex also activates so-called non-
Smad mediated pathways. These include MAP kinases (ERK, JNK, p38), Rho-like GTPase 
signaling and phosphatidylinositol-3-kinase/AKT pathways, which are especially relevant in 
epithelial to mesenchymal transition (EMT) (Zhang, 2009).  
The best characterized non-Smad mediators are JNK and p38 MAPKs, which are rapidly 
phosphorylated in response to TGF signaling by MAP kinase kinases, MEKK4 and MEKK3/6, 
respectively. Upstream, MEKKs are regulated by TGF-activated kinase 1 (TAK1), which is in turn 
regulated by TRAF6. Smads are not essential for the activation of JNK/p38 pathway, indicating that 
JNK/p38 are directly regulated by type I and type II receptors. TRAF6-TAK1-MEKK-JNK-p38 
pathways play an important role in TGF-induced apoptosis and EMT (Zhang, 2009).  
TGF induces major changes in the cell morphology and actin cytoskeleton during EMT. These are 
mediated by Smad-dependent and Smad-independent activation of Rho GTPases. Moreover, there 
seems to be a difference in long-term and short-term induction of EMT. RhoGTPases are first 
activated directly by type I and type II receptors, but later also activation of Smads seems to be 
needed. Smad2/3 trigger the activation of RhoA and RhoB GTPases and long-term actin 
reorganization (Vardouli et al., 2008). However, whereas RhoA is required for TGF-induced 
EMT, Smad signalling is not (Bhowmick et al., 2001).  
 
TGF in cancer progression 
TGF has a dual role in cancer; it acts as a tumor suppressor during the early stages of tumor 
development by inhibiting growth of endothelial and epithelial cells and by inducing apoptosis and 
terminal differentiation. In later stages of tumorigenesis TGF promotes cell motility and tumor 
metastases through EMT, suppresses immune system and induces angiogenesis. Tumors may 
acquire the ability to bypass the growth inhibiting properties of TGF, and exploit certain properties 
to actively promote tumor progression (Derynck and Akhurst, 2007). Different types of tumors such 
as gliomas, breast and prostate cancer seems to acquire preferential resistance to TGF-induced 
growth arrest, but retain the ability of TGF-induced EMT, metastatic dissemination and 
suppression of the immune system. Tumors with such signature are highly aggressive (Meulmeester 
and Ten Dijke, 2011).   
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As the TGF signaling cascade is a large network consisting of hundreds of factors, mutations in 
any of the genes along the pathway may have a severe impact on TGF signaling. As TGF also 
promotes tumorigenesis, increased expression by tumor cells correlates with metastatic lesions of 
breast, colon and prostate cancer progression (Meulmeester and Ten Dijke, 2011). TGF type II 
receptor and Smad4 are frequently inactivated by mutation or by loss of heterozygosity (LOH) in 
several types of carcinomas. TGFBR2 is especially affected in gastric tumors, gliomas and 
colorectal cancer, and SMAD4 in pancreatic, colorectal and head and neck cancers, suggesting that 
they are tumor suppressors (Levy and Hill, 2006; Meulmeester and Ten Dijke, 2011). In contrast, 
the inhibitory factors like Smad7, Smurf1/2 and SnoN/Ski are often overexpressed (Luo, 2004) in 
various carcinomas (Levy and Hill, 2006). High levels of Smurf2 inversely correlate to Smad2 
levels with higher invasion rate, lymph node metastases and with poor prognosis of esophageal 
SCC patients (Fukuchi et al., 2002). Smad7 was found to be more frequently lost than amplified in 
colorectal cancer, and loss of Smad7 was thought to sensitize the cells to tumor suppressor activity 
of TGF, whereas its amplification is thought to have an adverse effect. Interestingly, patients with 
deleted SMAD7 gene have better prognosis than patients with amplified SMAD7, implicating that 
resistance to TGF-mediated apoptosis is important in colorectal tumorigenesis (Boulay et al., 
2003). Ski/SnoN are thought to act as a oncogenes, as their overexpression transforms cells, and 
they are found overexpressed in several cancer cell lines (Luo, 2004). Moreover, in breast 
carcinoma high SnoN levels together with ERα+ -signature correlate with poor prognosis (Zhang et 
al., 2003). Betaglycan itself represses proliferation, migration and adhesion (Lambert et al., 2011), 
and the loss of betaglycan in several types of tumors supports its role as a tumor suppressor (Gatza 
et al., 2010).   
Although carcinomas are originated from adjacent epithelial tissue, the tumor surrounding tissue, 
called tumor microenvironment, including ECM, fibroblasts, immune cells (macrophages, 
lymphocytes, mast cells) and vasculature (endothelial cells, pericytes and smooth muscle cells) 
largely affects the tumorigenesis of the epithelial cells (Bhowmick et al., 2004). TGF is one of the 
paracrine factors that mediate the interaction between the tumor and the host tissue. TGF regulates 
non-cell-autonomous signaling, epithelial-stromal interactions, immune system evasion and 
angiogenesis in the tumor microenviroment (Bhowmick et al., 2004). TGF also regulates 
angiogenesis as high levels of TGF correlate with high level of vasculature in prostate cancer 
(Wikstrom et al., 1998). Also, high levels of TGF in plasma positively correlate with tumor 
vascularity in hepatocellular carcinoma (Ito et al., 1995). 
As excess TGF promotes tumor progression and apparently plays a major role in tumorigenesis of 
different types of tumors, several approaches have been taken to target and block TGF-signaling. 
These include: blocking the synthesis of TGF by antisense molecules, ligand traps (antibodies and 
soluble receptors) and small molecule inhibitors (Meulmeester and Ten Dijke, 2011). Antisense 
molecules have been developed against TGF-ligand and type II receptor, ligand traps include 
monoclonal antibodies and soluble type II and III receptor molecules, whereas small molecule 
compounds target the receptor kinase activities. One of the compounds, SB431542, (used in study 
III) blocks totally TGF-signaling by preventing Smad phosphorylation by type I receptor. 
Currently, several of these are under investigation in clinical trials, but although promising results 
exist, concerns in inhibiting TGF-signaling have arisen due to its role as a tumor suppressor 
(Meulmeester and Ten Dijke, 2011).   
 
TGF in epithelial-mesenchymal transdifferentiation  
Epithelial cells act as a protective barrier that line both the outer (skin) and inner (alveoli in lungs, 
gastrointestine) body compartments, and also function in secretory and glandular tissues. Epithelial 
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tissue has several functions depending on the organ where they are located ranging from nutrient 
absorption in intestines to gaseous exchange in lungs or lactation in mammary gland. Epithelial 
cells are under constant repair and renewal, and about 90% of the cancers are of epithelial origin 
(McCaffrey et al. 2011). 
Epithelial cells are immotile and polar cells, and are characterized by strong adhesions between 
neighboring cells. These cell-cell contacts include tight and adherens junctions, which are 
connected to the circumferential actin belt. A key component of the adherens junctions is E-
cadherin, which forms homophilic trans-interactions at sites of cell-cell contacts in the presence of 
Ca2+. This is vital for initiating and maintaining epithelial architecture in vitro and in vivo (Yilmaz 
and Christofori, 2009). E-cadherin is linked to the underlying actin cytoskeleton through  and  
catenins.  
During epithelial-mesenchymal transdifferentiation (EMT), epithelial junctions are disintegrated 
and cells become more motile and apolar fibroblast-cell like. EMT is a normal process during 
embryo development and wound healing, but occurs also during pathological conditions like 
carcinogenesis and fibrotic diseases. Molecular characteristics of EMT are loss of epithelial markers 
such as E-cadherin, zona occludens-1 (ZO-1), and the increase in mesenchymal markers like N-
cadherin,  smooth muscle actin (SMA), matrix metalloproteinases and ECM components 
including collagen and fibronectin (Rahimi and Leof, 2007).  
TGF plays an important role in EMT (Xu et al., 2009). TGF regulate the expression of well 
known EMT- inducer transcription factor families Snail, ZEB and bHLH (Xu et al., 2009; Micalizzi 
et al., 2010). In addition to the canonical TGF-signaling pathway, also non-canonical TGF-
induced signalling pathways induce EMT. Rho family of Small GTPases is important for cell 
adhesion, morphology and migration. RhoA promotes TGF-induced EMT in mammary epithelial 
cells (MEC), and inhibition of RhoA or its downstream effector ROCK leads to the inhibition of 
EMT (Bhowmick et al., 2001). Furthermore, miRNAs represent post-transcriptional regulators that 
bind complementary sequences on target mRNA. MiR-200 and miR-205 were found repressed 
during TGF-induced EMT. These miRNAs negatively regulate expression of E-cadherin 
transcriptional repressors ZEB1 and ZEB2. Expression of these miRNAs were found diminished in 
invasive breast cancer cell lines with mesenchymal properties implicating that downregulation of 
the miRNAs may be an important step during tumorigenesis (Gregory et al., 2008). 
 
Myofibroblasts in pathological conditions (in fibrotic diseases and in tumor progression)  
Myofibroblasts are cells with features of both fibroblasts and smooth muscle cells. Hallmarks of the 
myofibroblasts are extracellular matrix protein production, development of supermature focal 
adhesions and formation of contractile bundles composed of actin and myosin (Hinz et al., 2007).   
Myofibroblasts may differentiate from several origins; mesenchymal cells such as fibroblasts, 
hepatic stellate or smooth muscle cells, epithelial or endothelial cells through EMT, bone marrow 
cells or fibrocytes. Cells first differentiate transiently into promyofibroblast and then fully maturate 
into myofibroblasts that are characterized by de novo expression of SMA and of fibronectin splice 
variant ED-A (Hinz et al., 2007). 
TGF is an inducer of myofibroblast transdifferentiation as it increases the transdifferentiation of 
fibroblasts to myofibroblasts in vitro and in vivo (Desmouliere et al., 1993; Sime et al., 1997), 
respectively. TGF also promotes the myofibroblast differentiation of hepatic stellate cells 
(Gressner et al., 2002) and causes myofibroblast differentiation through EMT (Zavadil and 
Bottinger, 2005). TGF regulates SMA expression directly via Smad3 (Hu et al., 2003), and the 
regulation is mediated by two CArG elements (Hautmann et al., 1997). SMA has further been 
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shown to increase the contractility of the fibroblasts, and it is much more potent inducer of the 
contractility than cardiac  or -cytoplasmic actin (Hinz et al., 2001). 
Myofibroblasts are needed for normal wound repair. Activated myofibroblasts help the wound 
closure by secretion of matrix metalloproteinases, collagen and other ECM components and by 
contraction. After wound healing myofibroblasts normally disappear through apoptosis. However, 
repair process may become pathogenic, if they are not appropriately controlled. In fibrotic lesions 
activated myofibroblasts persist, and are responsible for excessive production of ECM that alters the 
tissue architecture leading to the organ failure (Hinz et al., 2007). Chronic inflammation and 
dysfunctional repair can trigger the excessive accumulation of ECM and lead to the formation of a 
permanent fibrotic scar (Wynn, 2008).  
Fibrosis is a pathological condition that can occur in various organs, such as lung, liver, kidney and 
cardiovasculature, and can be characterized by overgrowth, stiffening, scarring and excess 
production of ECM. It is usually caused by chronic inflammatory reactions induced by various 
stimuli including persistent infections, autoimmune reactions, allergic responses, chemical insults, 
radiation and tissue injury (Wynn, 2008). TGF has implicated to play a major role in fibrosis 
formation in many tissues, including the lung (Sime et al., 1997).  
Myofibroblast also contributes to tumor progression (Hinz, 2010). During tumor development, 
tissue homeostasis between different cell types is disturbed. The invasive nature of tumor cells is an 
end result of interaction between epithelial cells and the tumor stroma. The tumor stroma includes 
cancer associated fibroblasts (CAFs), immune cells, vasculature and extracellular matrix (De Wever 
and Mareel, 2003). CAFs are often present in carcinomas, and they play a role in tumorigenesis by 
secreting paracrine growth factors and in this way promote tumor growth, angiogenesis and 
invasion (Rasanen and Vaheri, 2010).  
 
Idiopathic pulmonary fibrosis (IPF) 
IPF is an interstitial lung disease characterized by uncontrolled production of extracellular matrix, 
formation of scar tissue and disruption of normal lung architecture. IPF has a poor prognosis and 
the 5-year survival is only 20% (Scotton et al. 2007). Chronic inflammation and accumulation of 
myofibroblasts as fibroblastic foci is observed in the lung leading to decreased alveolar gas 
exchange and pulmonary volume restriction (American Thoracic Society 2000).  
Usually, injury in the lung will lead to damage in epithelial or endothelial cells together with 
vascular leakage and edema. This will lead to the recruitment of inflammatory cells, activation of 
local coagulation pathways, ECM deposition and myofibroblast recruitment to promote wound 
contraction. To maintain the normal alveolar structure of the lung, the mesenchymal and 
inflammatory cells are then dismissed through apoptosis or phagocytosis. In IPF these processes are 
dysfunctional, and although the etiology of IPF disease is largely unknown persistent lung injury, 
inflammation and inefficient wound repair contribute to the disease. Furthermore, acquired or 
hereditary genetic alterations may predispose to IPF (Hardie et al., 2010). Pulmonary surfactant SP-
C is a lipoprotein complex that maintains alveolar stability during respiration and is needed for 
normal lung function. Several mutations have been found in SP-C coding gene SFTPC in 
individuals with family history of lung fibrosis (Hardie et al., 2010). Furthermore, mutations in 
telomerase reverse transcriptase TERT and RNA component of telomerase TERC have also been 
found in IPF families. Telomere shortening confers a dramatic increase in susceptibility to IPF 
(Tsakiri et al. 2007). 
A key process of repairing lung injury is the activation of TGF, and its uncontrolled activity 
contributes to IPF. An emerging concept has been that IPF is a disease of deregulated EMT 
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crosstalk (Coward et al., 2010). IPF can be triggered by alveolar injury that leads to the activation 
of TGFβ and alveolar basement membrane disruption. Activated TGFβ can then lead to enhanced 
epithelial apoptosis and EMT, as well as fibroblast and fibrocyte differentiation into myofibroblasts. 
Deposition of excess extracellular matrix by the myofibroblasts may then lead to the development 
of IPF (Coward et al., 2010). Elevated levels of TGF have been detected in IPF lung specimens as 
compared to the controls (Khalil et al., 1991; Bergeron et al., 2003), and the presence of TGF1 in 
the lung epithelium indicates chronic injury (Khalil et al., 1996). Polymorphism in the TGFB1 gene 
have been found in codons 10 and 25, and while they do not predispose to the development of IPF, 
they may affect the progression of the disease (Xaubet et al., 2003). Moreover, specific inhibitors of 
the type I receptor reduced myofibroblast transformation and collagen gel contraction in a rat 
bleomycin-induced lung fibrosis model (Kapoun et al., 2006).  
As TGF has been linked with the formation of IPF, several genes are reported to mediate the 
TGF- induced effect. NAPDH/oxidase 4 (NOX-4) belongs to a group of enzymes that catalyze the 
O2 to ROS and is required for TGF-induced myofibroblast differentiation, ECM production and 
contractility. Furthermore, silencing or pharmacological targeting of NOX-4 abrogated the 
formation of fibrosis in two murine models with lung injury (Hecker et al., 2009). Peroxisome 
proliferator-activated receptor-γ (PPAR-γ) has been shown to repress TGF-promoted 
myofibroblast differentiation via Smad-independent manner by affecting two TGF-dependent pro-
survival pathways involved in myofibroblast differentiation (Kulkarni et al., 2011). MiRNAs have 
been associated with formation of lung fibrosis/ IPF (Pandit et al., 2011). MiRNA-21 was found to 
be up-regulated in fibrotic bleomycin-induced mice and in IPF patients, and mediated the fibrogenic 
activity of TGF. Sequestration of miRNA-21 led to the abrogation of bleomycin-induced lung 
fibrosis (Liu et al., 2010). Another miRNA associated with IPF formation is let-7d, which is down-
regulated by TGF. Inhibition of Let-7d leads to the increase in mesenchymal markers such as N-
cadherin 2, vimentin and SMA, and is significantly reduced in IPF patient lungs (Pandit et al., 
2010). 
 
LIM- DOMAIN PROTEINS 
LIM domain was first characterized as a cysteine-rich sequence from a cDNA encoded by 
Caenorhabditis elegans MEC-3 gene which is required for the specification of the mechanosensory 
neurons. At that time there were no similar sequences found in databases until cloning of two other 
genes, LIN-11 (C. elegans lineage protein) and Isl1 (the rat insulin gene-enhancer-binding protein), 
which led to the identification of a new protein domain then named as LIM after LIN-11, Isl1 and 
MEC-3, respectively (Kadrmas and Beckerle, 2004). Individual LIM domains were characterized 
by sequence CX2CX16–23HX2CX2CX2CX16–21CX2(C/H/D) (where X denotes any amino acid) 
(Schmeichel and Beckerle, 1994), although human LIM domains were later noticed to show slightly 
a broader consensus sequence (Kadrmas and Beckerle, 2004). In general, LIM domains consist of 
50-60 amino acids and form two zinc fingers, which are separated by two amino acids as shown in 
Fig. 6 (Zheng and Zhao, 2007). Although zinc fingers are known as a DNA binding domains, no 




Figure 6. LIM domain. Eight zinc-binding residues (1-8) were identified and positioned based on analyzing 135 human 
LIM sequences. Infrequently observed amino acids (<10% of cases) are underlined and X represents any amino acid. 
Below the sequence, the topology of zinc coordination is shown. Numbered circles indicate the zinc-binding residues, 
and the semi-conserved residues are shown as black circles. Non-conserved residues are represented as grey circles. 
Dark grey circles indicate a variable number of residues (X) that are possible within the sequence. Modified from 
Kadrmas and Beckerle, 2004. 
 
LIM domains have been found in a wide variety of eukaryotes, and 135 LIM domains have been 
identified within 58 genes (Kadrmas and Beckerle, 2004). Some human LIM domain containing 
proteins comprise only of LIM domains, whereas some proteins carry other functional domains in 
addition to LIM domain, including homeodomains, catalytic domains, actin cytoskeleton binding 
domains or other protein-binding modules such as SH3, LD or PDZ domains. LIM domain proteins 
have been categorized into four groups (Fig. 7); the first group consists of N-terminal tandem LIM 
domain proteins such as LHX and nuclear LMO proteins, which are found in the nucleus and act as 
a transcription factors or cofactors. Second group of proteins consist of LIM-only proteins that can 
be found both from nucleus and cytoplasm, and these protein families include CRP, FHL and 
PINCH. The third and the fourth groups include proteins also carrying other functional domains. 
The third group proteins usually have a C-terminal LIM domain in addition to various other protein-
protein interaction motifs such as PDZ, LD (leucine-aspartate repeat) and ATD (actin-target 
domain) and these proteins include protein families Paxillin, Zyxin, Testin, Enigma, ALP, ZNF185, 
EPLIN, LASP and ABLIM. The fourth group of proteins carries in addition to LIM and protein-
protein interaction domains also mono-oxygenase or kinase catalytic motifs, like LIMK and 
MICAL proteins (Zheng and Zhao, 2007). 
LIM domain proteins have been identified both in cytoplasm and in nucleus. Whereas some are 
located solely in the nucleus and act as a transcription factors, most are associated with actin 
cytoskeleton in the cytoplasm. Several are able to shuttle between cytoplasm and nucleus, and 
extracellular stimulation, e.g. by UV, has been shown to trigger the translocation of zyxin to the 
nucleus (Hervy et al., 2010). Furthermore, zyxin responds to cell stretching by translocating from 
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focal adhesions into nucleus to regulate gene expression (Wojtowicz et al., 2010). Thus LIM 
domain proteins have been suggested to mediate signals between the nucleus and cytoplasm 
(Kadrmas and Beckerle, 2004).  
LIM domain mediates protein-protein interactions. The proteins may operate through interacting 
with other proteins by acting as adaptors, competitors, autoinhibitors or localizers. Diverse roles for 
LIM domain proteins have been suggested, such as development, gene expression, cytoarchitecture, 
cell adhesion and motility, signal transduction, cell fate determination and tumor formation 
(Kadrmas and Beckerle, 2004; Zheng and Zhao, 2007). These activities are mediated by protein-
protein interactions, and depending on their interacting protein partners a LIM domain protein may 
have several different functions (Zheng and Zhao, 2007). 
 
 
Figure 7. LIM domain family proteins as grouped based on their sequence and their function. (A) Group I consists of 
nuclear LHX proteins and LMO (LIM only) proteins. Group II consists of CRP, FHL and PINCH proteins, which only 
have LIM domains, but associate with actin cytoskeleton. Group III represents proteins that have other functional 
domains in addition to the LIM domains. Group IV consists of proteins that have catalytic activity in addition to LIM 
domain. Grey boxes represent LIM domain. Other domains are LD, ActA, PDZ, ATD, NeBR, SH3 and VHP. Figure 
(B) represents the protein families and their members grouped from I-IV. G=glycine rich repeat. Modified from Zheng 
and Zhao, 2007 and Kadrmas and Beckerle, 2004.  
 
LIM domain proteins in actin cytoskeleton 
Actin cytoskeleton is required for various cellular processes, and actin rich structures include focal 
adhesions, lamellipodia, filopodia, actin stress fibers, the cleavage furrow and the mitotic apparatus. 
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Actin may be present as a monomeric G-actin or form filamentous F-actin structures (Schmidt and 
Hall, 1998). Several LIM domain proteins regulate actin cytoskeleton linked processes, like actin 
bundling, stress fiber organization, migration and adhesion.  
Zyxin, a protein with five LIM domains, is a component of focal adhesions and regulates actin 
stress fiber reorganization and cell migration during TGF-induced EMT (Mori et al., 2009). Zyxin 
plays an important role if the stress fibers are damaged, as it promotes the recruitment of -actinin 
to the sites of local stress fiber damage to restore actin integrity, and -actinin together with VASP 
to promote repair and stabilization of the stress fiber (Smith et al., 2010). Furthermore, mechanical 
force may also translocate zyxin from focal adhesions to actin filaments (Yoshigi et al., 2005).  
RhoGTPases are the major regulators of actin cytoskeleton. Rho regulates stress fiber and focal 
adhesion assembly, Rac regulates the formation of lamellipodia and membrane ruffles and Cdc42 
triggers filopodial extensions (Schmidt and Hall, 1998). Several LIM domain proteins are directly 
regulated by RhoGTPases. EPLIN displays two distinctly regulated transcripts, and EPLINα is 
regulated by RhoA (Chen et al., 2000). LIMK 1/ 2, are serine protein kinases involved in the 
regulation of actin polymerisation and microtubule disassembly. Rho kinase (ROCK) regulates the 
activity of LIMKs by phosphorylation, and on the other hand LIMKs phosphorylate and inactivate 
the actin depolymerizing factors ADF/cofilin leading to the increase in filamentous actin (Bernard, 
2007). LIMK1 is involved in cancer metastasis (Wang et al., 2006), while LIMK2 activation 
promotes cells cycle progression (Sumi et al., 2006). 
Migration is a process facilitated by actin cytoskeleton, and needed during normal development, 
chemotactic migration of inflammatory cells and wound healing, but it may also be involved in 
pathological processes by providing the possibility for cancer cells to metastasize (Hall, 2009). 
Proteins localized in focal adhesions or actin cytoskeleton often participates in cell migration. 
PINCH1 is a protein with five tandem LIM domains and required for cell-ECM adhesion. PINCH1 
regulates cell adhesion and cell spreading via two distinct interactions. Interaction between its LIM 
domain and integrin-linked kinase is needed for cellular adhesion, whereas interaction between its 
C-terminal region and Ras suppressor protein 1 is needed for cellular spreading (Ito et al., 2010). 
Ajuba is localized into cellular adhesive complexes, and silencing of Ajuba leads to abnormal 
migration due to the abnormal formation of lamellipodia. Ajuba regulates the cell migration by 
recruiting p130Cas, a major Src substrate, to nascent adhesion sites. This is needed for activation of 
Rac and to formation of lamellipodia (Pratt et al., 2005).  
LASP-1, a protein with LIM and SH3 domains, binds actin and regulates cell migration (Lin et al., 
2004). LASP-1 interacts with chemokine receptor CXCR2 and this interaction is critical for 
CXCR2-mediated chemotaxis in neutrophils, macrophages and endothelial cells (Raman et al., 
2010). FHL2 is another LIM domain protein involved in inflammatory cell migration as it regulates 
chemotactic factor-induced dendritic cell migration (Konig et al., 2010). Also LIM-domain proteins 
FHL3, Mystique and LMO7 participate in the regulation of cell motility. FHL3 enhances cell 
spreading by inhibiting the actin bundling properties of α-actinin and thereby promotes actin 
disassembly (Coghill et al., 2003). Mystique (PDLIM2) is required for cellular adhesion and 
migration (Loughran et al., 2005) and LMO7 mediates cell-specific activation of Rho-MRTF-SRF 
pathway and promotes the breast cancer cell migration (Hu et al., 2011).  
 
LIM domain proteins in growth and tumorigenesis 
LIM domain proteins display various functions in the cell and have also been associated with cell 
growth and tumorigenesis. LIMK2 has been linked with regulation of actin cytoskeleton, but is also 
involved in cell division and required for the formation of a proper mitotic spindle (Po'uha et al., 
2010). Moreover, ectopic expression of splice variant LIMK2b has been shown to inhibit 
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cytokinesis by inactivating the function of cofilin leading to the formation of multinucleated cells 
(Hsu et al., 2010). Overall, LIMK2b has been implicated as a tumor suppressor as it is 
downregulated in esophageal and thyroid cancers and in number of established cancer cell lines 
(Hsu et al., 2010). Zyxin is specifically phosphorylated during mitosis, and localizes and interacts 
with h-warts/LATS1 complex in the mitotic apparatus. Inhibiting the mitotic localization of zyxin 
prolongs the duration of mitosis significantly (Hirota et al., 2000). Furthermore, zyxin shows tumor 
suppressor properties in Ewing sarcoma cells, since re-expression in the cells reduces the migration, 
inhibits anchorage-independent growth and impaires tumour formation in mice (Amsellem et al., 
2005). 
RIL is LIM domain protein that suppresses cell growth. Its gene is localized on chromosome 5q31, 
a region commonly deleted in acute myelogenous leukemia and myelodysplastic syndrome, and is 
silenced by methylation in several cancer cell lines. Furthermore, methylation of RIL is a marker 
for poor prognosis in myelodysplastic syndrome (Boumber et al., 2007). LIM domain-containing 
protein 1 (LIMD1) functions through interaction with retinoblastoma protein (pRB), and therefore 
inhibits E2F-mediated transcription and suppresses cell growth (Sharp et al., 2004). LIMD1 was 
also identified as a tumor suppressor, as it is frequently deleted in many solid malignancies. FHL 1-
3 inhibited anchorage dependent and independent growth of human hepatoma cell line in vitro and 
tumour formation in vivo (Ding et al., 2009). 
Mystique (PDLIM2) suppresses anchorage-independent growth and tumor formation by inhibiting 
the function of NFκB, which becomes constitutively activated during colon tumorigenesis. 
Mystique is repressed in various human colorectal cancer cell lines and the repression involves 
promoter methylation. As restoring the mystique expression resulted in growth arrest, it has been 
suggested to act as a tumor suppressor in colorectal (Qu et al., 2010b) and breast cancer (Qu et al., 
2010a). 
Although several LIM domain proteins function or are putative tumor suppressors, also oncogenic 
LIM domain proteins exist. LMO proteins are transcription factors and have frequently been 
associated with cancer development. LMO1 and LMO2 act as oncogenic proteins in acute T-cell 
lymphoblastic leukemia, and both LMO1 (Wang et al., 2011) and LMO3 (Aoyama et al., 2005) are 
identified as oncogenes in neuroblastoma. Moreover, LMO4 contributes to the development of 
breast cancer (Zheng and Zhao, 2007) and is overexpressed in late stage pancreatic cancer (Yu et 
al., 2008). Silencing studies of LMO4 revealed that LMO4 may promote cell growth and survival of 
both normal mammary epithelial and breast cancer cells (Visvader et al., 2001; Tian et al., 2010).  
 
LIM domain proteins in cellular stress and fate decisions 
Several LIM domain proteins are phosphorylated or activated in response to DNA damage and cell 
stress, and play a role in cell fate decision between survival or apoptosis. As p53 has a crucial role 
in repair, several LIM domain proteins have been shown to be p53 targets and/or to modulate p53 
dependent pathway through protein-protein interactions.  
Zyxin is phosphorylated and accumulates into the nucleus from focal adhesions in response to 
UVC-irradiation (Hervy et al., 2010). Zyxin interacts with cell cycle and apoptosis regulator 
protein-1 (CARP-1) in response to UVC and promotes apoptosis of cells (Hervy et al., 2010). Zyxin 
also regulates apoptosis in response to DNA damage via HIPK2-p53 pathway (Crone et al., 2011). 
HIPK2 activates the apoptotic response of the cells in response to DNA damage by phosphorylating 
p53 at serine 46. Normally, levels of HIPK2 are kept low by siah-1 and WSB1, however, DNA 
damage causes zyxin to regulate siah1 activity by interfering with its dimerization. As silencing of 
zyxin results in attenuated HIPK2 protein levels and reduces DNA damage-induced p53 Ser46 
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phosphorylation and caspase activation, zyxin is implicated to regulate HIPK2-p53 signaling and to 
contribute apoptosis in response to DNA damage (Crone et al., 2011). 
LIMK2 is a direct p53 target gene and promotes the survival of the cells in response to damage 
(Croft et al., 2011). Also the splice variant LIMK2b has been described as a p53 target and shown 
to be needed for G2/M arrest after DNA damage. Furthermore, it was suggested that LIMK2b 
regulates G2/M arrest through phosphorylation of cofilin and thus by modulating the dynamics of 
actin polymerization (Hsu et al., 2010). As expression of LMO3 suppresses the expression of p53 
dependent target genes, but still facilitates p53 binding to its response elements, LMO3 has been 
implicated to act as a co-repressor of p53 (Larsen et al., 2010). Moreover, enigma negatively 
regulates p53 through MDM2 by inhibiting MDM2 self-ubiquitination and increasing its ubiquitin 
ligase activity towards p53 in cells. Furthermore, enigma promotes cell survival and 
chemoresistance by suppressing p53-mediated apoptosis in cell lines and in mice (Jung et al., 
2010). 
RIL expression sensitizes cancer cells to apoptosis, as RIL expression in colon cancer cells results 
in reduced cell growth and clonogenicity and an approximately 2.0-fold increase in apoptosis 
following UV exposure (Boumber et al., 2007).  
FHL2/ DRAL is a transcriptional target of p53, and five potential p53 target sites have been 
identified in human FHL2/ DRAL gene. Furthermore, FHL2/ DRAL expression efficiently triggers 
apoptosis in three cell lines of different origin (Scholl et al., 2000). The transcription factor E4F1 is 
one of the key players in controlling mammalian embryonic and somatic cell proliferation and 
survival, and its antiproliferative effects have been shown to depend on its capacity to repress 
transcription and to interact with pRb and p53. FHL2 is negative regulator of E4F1 thus inhibiting 
its ability to promote cell proliferation. E4F1-FHL2 complexes form upon UVR-induced nuclear 
accumulation of FHL2 (Paul et al., 2006). Besides the damage- induced cell death, LIM domain 
proteins participate in apoptosis e.g. during development. Sonic hedgehog (SHH) and its main 
receptor, Patched (PTC), are implicated in both neural development and tumorigenesis. SHH is a 
survival factor, whereas PTC induces apoptosis in the absence of SHH. PTC triggers caspase 9 
activation and promotes cell death through a caspase 9-dependent mechanism. In the absence of 
SHH, PTC serves as an anchor for a caspase-activating complex that includes FHL2/ DRAL and 
caspase 9. FHL2/ DRAL is required for the pro-apoptotic activity of PTC both in immortalized cells 














Table 1. Summary of LIM- domain proteins playing a role in cell proliferation and/ or in tumour formation.  
PROTEIN 
 












I act as oncogenes  
LMO4 promotes cell growth and 
survival of both normal mammary 
epithelial and breast cancer cells 
LMO1/2 in acute T-cell 
lymphoblastic 
leukemia, LMO 1/3 in 
neuroblastoma, 
LMO4 in breast 
carcinoma and 
pancreatic cancer 







inhibit anchorage dependent and 
independent growth of human 
hepatoma cell line in vitro and 
tumor formation in vivo 




FHL2/ DRAL is a 
transcriptional target of 
p53, expression  
triggers apoptosis  
zyxin III inhibition prolongs the duration of 
mitosis significantly 
tumor suppressor 
activity in Ewing tumor 
cells 
is phosphorylated and 
accumulates in nucleus 
in response to UVC-
irradiation and 
promotes apoptosis of 
cells  
regulates apoptosis via 
HIPK2-p53 pathway 
LIMD1 III interacts with retinoblastoma 
protein (pRB), and inhibits E2F-
mediated transcription and 
suppresses cell growth 








of RIL is a marker for 




sensitizes cancer cells 






independent growth and tumor 
formation 
repressed in various 
human colorectal 
cancer cell lines by 
promoter methylation, 
acts as a tumor 
suppressor in colorectal 
and breast cancer 
 
EPLIN III depletion enhances EMT, 
proliferation, migration and 
invasion, and its downregulation 
correlates with metastases 
SCC of head and neck 
cancers 
 
LIMK2 IV required for formation of proper 
spindle 




IV overexpression inhibits 
cytokinesis and leads to 
multinucleated cells 
downregulated in 
esophageal and thyroid 
cancers and in several 
cancer cell lines 
novel p53 target and 
shown to be needed for 
G2/M arrest after DNA 
damage 
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LIM domain proteins in TGF-signaling pathway 
Several LIM domain proteins are involved in TGF-signaling pathway, and activation of TGF1 
induces several LIM domain proteins. The expression of CRP2 is regulated by TGF in vascular 
smooth muscle cells (VSMC) and in hepatic stellate cells. TGF transcriptionally induces CSRP2 
via type I receptor (Herrmann et al., 2006) and activating transcription factor 2 (ATF2). Silencing 
of CRP2 leads to the increased migration of VSMCs, and the migration is further enhanced by 
TGF-treatment (Lin et al., 2008). 
Hydrogen peroxide-inducible clone 5 (Hic-5/ARA55) is a coactivator of androgen receptor (AR). It 
is expressed in prostate stroma and has four LIM domains. It modulates TGF--signaling by 
interaction with Smads. Hic-5 interacts with Smad3, Smad4 (Wang et al., 2005) and Smad7 (Wang 
et al., 2008), but not with Smad2 (Wang et al., 2005). Hic-5 suppresses Smad7 by physically 
interacting with Smad7 through its third LIM domain inducing Smad7 loss (Wang et al., 2008). The 
same third LIM domain is also needed for interaction between Hic-5 and Smad3, which leads to the 
downregulation of Smad3 mediated signaling (Wang et al., 2005). Furthermore, suppressive 
activity of Hic-5 on Smad3 and Smad7 enhances Smad2 activity, thus suggesting that TGF 
responses depend on the balance on Smad3- and Smad2- dependent signals (Wang et al., 2008).  
LMO1 is a nuclear LIM domain protein with no binding ability to DNA, and it regulates Gasdermin 
in TGF-dependent manner and functions in TGF-induced apoptosis in the gastric epithelium 
(Saeki et al., 2007). Zyxin is another target of TGF signaling cascade, and is required for stress 
fiber reorganization and cell migration during EMT in mouse mammary gland epithelial cells 
(NMuMG) and in endocardial cells through transcription factor Twist1 (Mori et al., 2009). LIMK 
together with Rho kinase (ROCK) is required for TGF-stimulated transcriptional activity of SRF 
and actin stress fiber reorganization during EMT. Furthermore, LIMK is not required for TGF-
induced 2D motility, but is needed for TGF-induced cell invasion in matrix (Morin et al., 2011).   
FHL proteins (FHL1, FHL2, FHL3) interact with Smads (Smad2, Smad3, Smad4) and regulate 
TGF-responsive transcription by enhancing Smad2/3 phosphorylation, Smad2/3 and Smad4 
interaction and nuclear accumulation via casein kinase 1δ (CK1δ) independently of TGF-receptor 
signaling. In hepatocellular carcinomas, FHL proteins are often downregulated, and the levels 
correlate with decreased TGF-like responses in the clinical samples (Ding et al., 2009).  
 
THE FAMILY OF CYSTEINE RICH PROTEINS  
CRP family consists of three members: CRP1, CRP2 and CRP3/MLP (Weiskirchen et al., 1995). 
TLP (thymus LIM protein) is closely related, and sometimes referred as a fourth member of the 
family (Kirchner et al., 2001). CRPs are small proteins, 22 kDa of size, and comprise of two 
functional LIM domains, each of them linked to glycine-rich repeat.  
Several related proteins have been found to share common features with the CRP vertebrate 
counterparts, suggesting that these proteins are evolutionarily conserved. CRP like LIM domain 
proteins have been identified in arthropods, protozoas and plants. Two members of CRP counterpart 
in Drosophila melanogaster have been found and referred to as MLP (Weiskirchen and Günther, 
2003). DdLIM is considered as CRP counterpart in Dictyostelium discoideum, and although it has 
similarities to CRP proteins, DdLIM only contains one LIM domain, it has no putative nuclear 
targeting signal and a very diffuse glycine-rich repeat (Prassler et al., 1998). 
It is noteworthy that most plant LIM domains actually are related to CRP family (Thomas et al., 
2007a). Although plant LIM proteins share similar structure with two LIM domains, they also show 
distinct features. Plant LIM domain proteins lack glycine rich repeats, and have impaired second 
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LIM domain. WLIM has two LIM domains, binds actin and bundle actin filaments and has two 
different isoforms (Thomas et al., 2006; Thomas et al., 2007b).  
CRPs exhibit a differential expression pattern in chicken; CRP1 expression is detected in most of 
the tissues, especially enriched in smooth muscle cells, whereas CRP2 is restricted to arteries and 
fibroblasts and CRP3/mlp to striated muscle (Louis et al., 1997). However, when expressed in 
fibroblasts, a common feature for these proteins is association with actin cytoskeleton, and 
interaction with -actinin and zyxin (Louis et al., 1997). The carboxyl-terminus of CRPs (LIM2) is 
predicted to have at least one protein partner and CRP3/mlp also interacts with 1-spectrin (Flick 
and Konieczny, 2000). Thus it has been suggested that although CRPs have common interacting 
protein partners, binding proteins may also differ from one another allowing the different functions 
in the cell.  
 
Csrp1/ CRP1 
Human CRP coding gene (Csrp1) was first cloned 1990 (Liebhaber et al., 1990). The cDNA was 
described to be 1778 bp in length, and to carry duplicated domains each with two putative zinc 
fingers and glycine-rich repeats. It seems to be very well conserved in evolution from yeast to 
human. It is represented as a single copy in human genome, and localizes to chromosome 1q24-
1q32 (Wang et al., 1992; Erdel and Weiskirchen, 1998). CRP1 has also been cloned from chicken 
(Crawford et al., 1994). 
Significant structural similarities exist between CRP1 and cysteine-rich intestinal protein (CRIP). 
CRP1 contains four zinc fingers consisting of a 25 amino acid domain, whereas CRIP only consists 
of two zinc fingers. Based on the sequence similarities between zinc fingers 1-3 and 2-4, it has been 
suggested that CRP1 might have evolved as duplication of CRIP gene (Liebhaber et al., 1990). Four 
human transcripts have been found. As CRP1 and CRP2 are highly identical, CRP genes are 
predicted to have arisen of the common ancestor probably through gene duplication (Lilly et al., 
2001).  
The three dimensional structure of chicken CRP1 has been determined by multidimensional nuclear 
magnetic resonance (NMR). The structure analysis showed that two LIM domain components are 
spatially separated with no interaction between one another, suggesting that they may function as 
independent units as an adapters or linkers. CRP1 has also been suggested to occur as monomers 
(Yao et al., 1999). CRP1 also carries a putative nuclear localization signal in its sequence 
(Weiskirchen et al., 1995).  
 
Regulation of CRP1 expression 
CRP1 is expressed both in vascular and nonvascular tissues containing smooth muscle cells (Yet et 
al., 2008) and it has been suggested to act as a smooth muscle marker (Henderson et al., 1999). In 
chicken, CRP1 protein is most prominently expressed in intestine, stomach and gizzard tissue which 
are enriched with smooth muscle cells (Crawford et al., 1994). Furthermore, Csrp1 mRNA was 
found by northern blotting to be strongly expressed in brain, lung and kidney and with weaker 
staining in heart, spleen, skeletal muscle and testis in mice (Henderson et al., 1999). Under more 
careful investigation, CRP1 was found expressed prominently in smooth muscle cells in different 
mouse tissues. Hybridization of Csrp1 probe revealed that Csrp1 transcript was found specifically 
in smooth muscle cells of adult murine cardiac arteries, but not in cardiac muscle tissue itself. CRP1 
is also expressed abundantly in stromal compartment of the human prostate, where CRP1 is 
strongly expressed in cytoplasm, and with no significant staining in the secretory epithelium (Dube 
et al., 1998).  
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SRF regulates transcriptionally many smooth muscle specific genes containing CArG box enhancer 
elements in response to numerous stimuli causing reorganization of the actin cytoskeleton (Olson 
and Nordheim, 2010). SRF regulates the transcription of smooth muscle specific genes by binding 
to CArG-box in the promoter region. In Csrp1 the CArG-box is located in the 5.0 kb enhancer, and 
binding of SRF in this element is needed to direct the expression in arterial but not in venous or 
visceral smooth muscle cells (Lilly et al., 2001).  
Ca2+ signaling promotes the activation of many downstream effectors, including Ca2+/calmodulin 
(CaM)-dependent protein kinases consisting of three members: CaMKI, CaMKII, and CaMKIV. 
CaMKIV, but not CaMKII can induce CRP1 expression through the CRE and CArG box regions in 
the promoter (Najwer and Lilly, 2005). 
 
Function of CRP1 
Serum induction after starvation provokes the cells to switch from arrested to proliferative state of 
growth. The genes upregulated during the switch are called early immediate response genes and 
include transcription factors and proto-oncogenes (Bravo, 1990; Lau and Nathans, 1985). Csrp1 is 
one of the genes induced in response to growth factor stimulation in parallel with Myc-oncogene, 
and is therefore considered to play a role in cell growth and differentiation. Furthermore, early 
studies showed that CRP1 is dramatically reduced in transformed avian fibroblasts, emphasizing the 
possible role of CRP1 in cell transformation (Wang et al., 1992). 
Both CRP1 and CRP2 have been implicated to act as a potential smooth muscle differentiation co-
factors, because they are highly expressed in smooth muscle cells and able to interact with SRF and 
GATA6 transcription factors and to enhance the transcription of the SMA-reporter (Chang et al., 
2003). However, Csrp1 knock out mice, as well as Csrp1/ Csrp2 double knock out mice, were 
viable and fertile, and showed no distinguishable phenotype as compared to wild type counterparts 
(Lilly et al., 2010). Interestingly, the knock out of Csrp1 leads to the attenuated (Lilly et al., 2010) 
and knock out of Csrp2 to increased neointima formation after balloon surgery and in double knock 
out mice the formation of neointima is comparable to wild type. Therefore, it was suggested that 
smooth muscle-associated CRP1 and CRP2 are not essential for normal smooth muscle 
differentiation during development, but they may modulate the smooth muscle response during 
pathophysiological stress (Lilly et al., 2010). 
In zebrafish model, CRP1 acts as an important factor during gastrulation and cell movement of the 
mesoderm and cardiac mesoderm. Convergent extension is the process that plays a crucial role in 
organization of the cells during embryogenesis and during it the tissue is restructured to narrow 
along one axis and elongate along another axis by cellular movement. Wnt signalling pathway is 
essential for convergent extension during morphogenesis and CRP1 interacts with Wnt signalling 
pathway components Dishevelled and Diversin. CRP1 inhibition leads to abnormal cell movement 
in convergent extension resulting in deformities in midline structures (Miyasaka et al., 2007).  
CRP1 exhibits dual localization patterns in cell; it is found both in nucleus and in cytoplasm. In 
nucleus, CRP1 functions as a transcriptional co-regulator (Chang et al., 2003). CRP1 interacts with 
actin cytoskeleton in two ways; indirectly via interaction with known actin binding proteins, like -
actinin (Pomies et al., 1997) and zyxin (Sadler et al., 1992). Both LIM domains of CRP1 and the 
first of the three LIM domain of zyxin are needed for this interaction (Schmeichel and Beckerle, 
1998). However, LIM domains are not needed for alpha-actinin binding, but lysine 65 in N-terminal 
glycine-rich repeat is (Harper et al., 2000). CRP1 also directly interacts with actin. CRP1 may play 
a role in actin cytoskeleton remodeling by bundling the stress fibers by crossing actin filaments and 
by stabilizing the interactions of -actinin with actin filament bundles (Tran et al., 2005; Jang and 
Greenwood, 2009).  
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LIM domains of different LIM domain proteins have also been noticed to interact with PKC, as was 
the case with CRP1 as well (Kuroda et al., 1996). However, CRP1 does not affect the activation of 
PKC (Maturana et al., 2011).  
 
Csrp2/ CRP2  
Csrp2 gene was first cloned from rat (Okano et al., 1993) and later also from human and localized 
to chromosome 12q21.1 (Weiskirchen et al., 1997).  
CRP2 localizes to actin cytoskeleton and in addition to its interaction with -actinin and zyxin, 
CRP2 also binds actin directly (Grubinger and Gimona, 2004). CRP2 also interacts with STAT1-
protein through its C-terminal LIM domain (Weiskirchen et al., 2001) and with cysteine rich protein 
2 binding protein (CRP2BP), although the relevance of these interactions remains unclear 
(Weiskirchen and Gressner, 2000). Like several other LIM domain proteins, CRP2 is also regulated 
by TGF, and expressed under TGF-regulated control in hepatic stellate cells and in vascular 
smooth muscle cells (Herrmann et al., 2006; Lin et al., 2008).   
CRP2 is mostly expressed in smooth muscle cells, especially in vasculature (Yet et al., 1998). 
Moreover, the expression of CRP2 in adult vasculature is mediated through intronic CArG box 
(Chen et al., 2010). The role of CRP2 in vascular development was studied in Csrp2 knock out 
mice and it had no clear effect on vascular development (Wei et al., 2005). This was further 
supported by the data from Csrp1/ Csrp2 knock out study, where double knock out showed no 
difference in smooth muscle tissue (Lilly et al., 2010). Silencing of CRP2 enhanced vascular 
smooth muscle cell migration and lead to the increased neointima formation following arterial 
injury (Wei et al., 2005).  
However, CRP2 is transiently expressed in heart during embryogenesis and has a role in cardiac 
muscle differentiation. Cardiomyocyte-specific expression of transgenic CRP2 switches on smooth 
muscle gene expression in cardiac myocytes in mice (Chang et al., 2007). In this study CRP2 was 
suggested to function as a transcriptional co-adaptor protein (Chang et al., 2007). Moreover, 
targeted disruption of Csrp2 gene resulted in subtle changes in cardiac ultrastructure, although mice 
with non-functional CRP2 were otherwise viable and fertile. The thickness of the cardiomyocytes 
was increased and the cells were hypertrophic (Sagave et al., 2008).  
 
Csrp3/ CRP3/ MLP 
CRP3/MLP was first isolated as a cDNA from rat skeletal muscle (Arber et al., 1994). CRP3 has 
turned out to be the most extensively studied member of CRP family, and it is expressed in both 
cardiac and skeletal striated muscle cells.  
Skeletal muscle differentiation starts by embryonic stem cells developing into muscle precursor 
cells known as myoblasts, which then withdraw from cell cycle, fuse into multinucleated cells and 
start to express a large number of muscle-specific genes. Myogenesis is a complex event regulated 
by multiple signaling pathways, one of them being muscle regulated factors (MRF) including helix-
loop-helix transcription factors MyoD, MRF4, myogenin and Myf-5 which interact with E proteins. 
CRP3 is a positive regulator of myogenic differentiation, and overexpression of CRP3 in myoblasts 
enhances skeletal myogenesis. On the other hand, myoblasts with silenced Csrp3 fail to exit cell 
cycle and block terminal differentiation. CRP3 accumulates into nuclei at the beginning of muscle 
differentiation and later during the development it is observed in the cytoplasm (Arber et al., 1994). 
Furthermore, CRP3 has been identified as a cofactor in myogenesis inducing complex, which 
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interacts in nucleus with MyoD, myogenin and MRF4 through its first LIM domain and the helix-
loop-helix motifs of the MRFs (Kong et al., 1997).  
The Csrp3 knock out mice are viable and born in expected ratio, but already at birth, the hearts are 
abnormally soft, and have alterations in actin cytoskeleton. Subsequently, the disruption of Csrp3 
leads to the development of dilated cardiomyopathy with hypertrophy and heart failure. Further 
analyses of the cardiomyocytes show disruption of cytoarchitecture (Arber et al., 1997). The 
phenotype of Csrp3 knock out mice resemble the appearance of hypertrophic cardiomyopathy, 
which in humans is a hereditary disease of myocardium, where for unknown reason the 
myocardium is thickened. It is the most common cause of sudden cardiac death in young 
individuals. Csrp3 knock out mice were the first genetically altered mouse model that mimicked the 
disease, and consequently, CRP3 has been widely used experimental model in cardiology 
(Buyandelger et al., 2011). Moreover, mutations in Csrp3 gene have been found in families with 
hypertrophic cardiomyopathy (Geier et al., 2003), and CRP3 was found to be down-regulated in 
humans with heart failure (Zolk et al., 2000).  
CRP3 appears to be needed for adaptation of adult heart to the hemodynamic changes after birth 
(Buyandelger et al., 2011). CRP3 has been associated with stress in striated muscle, and to be 
induced during several different in vivo and in vitro experimental settings such as cell stretch 
(Campos et al., 2009), mechanical stimulation after Botulinum neurotoxin-A injection (Velders et 
al., 2008), fatiguing exercise (Lehti et al., 2009) and lengthening and shortening contractions 
(Kostek et al., 2007).  
Like all CRPs, CRP3 has been associated with actin cytoskeleton. It interacts with cofilin, and 
regulates F-actin dynamics in cardiac and skeletal muscle (Papalouka et al., 2009). Furthermore, 
CRP3 interacts and co-localizes with -spectrin at the sarcolemma overlying the Z- and M-lines of 



















Table 2. This table summarizes the literature of CRP-family including the tissues where particular protein of the family 
is expressed, binding partners and knock-out/ knock-in mice phenotypes. VSMC= vascular smooth muscle cell, 







KNOCK-OUT/ KNOCK-IN PHENOTYPE 











knock out mice: viable, fertile  
no effect on smooth muscle differentiation 
attenuated neointima formation after balloon surgery 
knock out zebra fish: abnormal cell movement during 
development 








knock out mice: viable, fertile 
no effect on smooth muscle differentiation 
knock out mice: no effect on vascular development 
enhanced VSMC migration  
increased neointima formation following arterial injury 
knock out mice: subtle changes in cardiac ultrastructure 
knock in mice: transgenic CRP2 switches on SMC-gene 
expression in cardiac myocytes 







knock out mice: viable and born in expected ratio, hearts 
abnormally soft, cardiomyocytes show disruption of 
cytoarchitecture,  leads to the development of dilated 
cardiomyopathy 






AIMS OF THE STUDY  
 
This study is based on a microarray study detailing UV-regulated transcriptome aiming at 
identifying transcripts induced with low and high dose of UVC in normal human skin fibroblasts 
(Gentile et al., 2003). The initial aim of this thesis was to identify and functionally characterize 
novel UV-regulated genes. Csrp1 was found to be induced by low and high dose of UVC. We set a 
hypothesis that CRP1 is needed during UVR-induced cell stress. The aims of this study were: 
 
1. To study UV-induction of Csrp1 and the functional role of CRP1 in UVR-induced cell 
stress. 
2. To study CRP1 regulation by UVR using physiologically relevant wavelengths and doses in 
human keratinocytes and in the human skin. 
3. To study the function and regulation of CRP1.   
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MATERIALS AND METHODS 
MATERIALS 
Cell lines 
Several cell lines were used in this study including normal human skin fibroblasts (WS1), 
spontaneously immortalized mouse fibroblasts (NIH3T3), human cervical cancer cell line (HeLa), 
human lung adenocarcinoma cell line (A549), human epidermoid carcinoma cell line (A431), 
embryonic kidney cells (293-T), spontaneously immortalized keratinocytes (HaCat) and fibroblasts 
isolated from human IPF patients. All the cell lines were maintained in DMEM supplemented with 
10 % FCS, except NIH3T3 which were supplemented with new born calf serum. Additionally, WS1 
cells were supplemented with non-essential amino acids and HaCaT cells with L-glutamine. All 
cells were maintained in +37C atmosphere containing 5 % CO2.  
UV-treatment of the cells were carried out by using UVB (312 nm) or UVC (254 nm) with 
Stratalinker 2400 UV crosslinker (Stratagene, La Jolla, CA). 
 
Antibodies 
Primary antibodies used were monoclonal anti-CRP1 antibody (BD Transduction Laboratories, 
Franklin Lakes, NJ), polyclonal anti-CRP1 (Abcam), rabbit polyclonal antibody raised against 
GST-CRP1 fusion protein in New Zealand rabbits (I), monoclonal anti-GAPDH (clone 9.B.88, 
Europa Bioproducts Ltd, Cambridge, UK), monoclonal anti-Smad2/3 (BD Transduction 
Laboratories), phosphospecific antibody for phospho-Smad2/3 (kindly provided by Dr. C. H. 
Heldin, Ludwig Institute for Cancer Research, Uppsala, Sweden), phosphospecific antibody for 
phospho- p38/MAPK Thr 180/Tyr 182 (Cell Signaling Technology, Danvers, MA), mouse 
monoclonal αSMA (Sigma Aldrich, St Louis, MO), polyclonal anti-PARP (Cell Signaling 
Technology), monoclonal anti-Myc (clone 9E10, Nordic Biosite AB), monoclonal α-actinin (H-2 
Santa Cruz), anti-p53 (DO-1), -tubulin (BD Pharmingen) and anti-Flag (M2 Sigma Aldrich).  
 
Plasmids 
Human Csrp1 cDNA was cloned from cDNA clone 690545 (ATCC). Csrp1 was subcloned to 
pAMC pC1-neo (Promega, Madison, WI) for Myc-tag, Flag-CMV-2 (Stratagene) for Flag-tag and 
to pEGFP-C2 (Clontech, Palo Alto) for EGFP-fusion protein. All tags were cloned in N-terminus of 
CRP1. CMV-promoter driven -galactosidase plasmid was used as a transfection control. p53 and 
p53 mutant (p53R273H) were cloned in pcDNA3. ShRNA constructs for silencing of CRP1 were 
cloned in pENTRTM (Invitrogen) or in pDSL_hpUGIH (Invitrogen).    
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Small molecule inhibitors 
Inhibitors used in this study were staurosporine (LC Laboratories, Woburn, MA), actinomycin D 
(Sigma Aldrich), 12-O-tetradecanoylphorbol-13-acetate (TPA, Sigma Aldrich), cyclohexamide 
(Calbiochem, Darmstadt, Germany), Smad3 inhibitor (SIS3, Calbiochem), p38 inhibitor 
(SB203580, Tocris, Bristol, UK), TGF- type I receptor inhibitor (SB431542, Sigma Aldrich) and 
caspase inhibitor VI (z-VAD-FMK, Calbiochem). 
 
Growth factors 
TGF was purchased from Peprotech EC (London, UK). 
 
Tissue samples 
Human tissue samples, fixed in formalin and embedded in paraffin, were obtained as collaboration 
either from Department of Dermatopathology, University of Helsinki (II) or from Department of 
Medicine, Division of Pulmonary Medicine, University of Helsinki (III). The use of all samples was 




Preparation of cellular extracts and immunoblotting (I, II, III) 
Monolayered cells were washed with phosphate buffered saline (PBS), scraped from the plates and 
lysed in EBC buffer (25 mM Tris-HCl pH 8.0, 120 mM NaCl, 0.5% NP-40, 4 mM NaF, 100 M 
Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 100 KIU/ml aprotinin and 10 g/ml leupeptin). The 
samples were then incubated on ice for at least 20 minutes followed by centrifuging the cells for 15 
minutes at 14 000 rpm. Protein concentration was measured by using Bio-Rad DC protein assay kit, 
protein samples were normalized and boiled in LSB-DTT for 5 minutes.   
Lysates were separated by using 10-12.5 % sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) followed by transfer of proteins to nitrocellulose membrane (Trans-
Blot, Transfer Medium, Bio-Rad) by using wet blot-method. The membranes were then blocked 
using 5 % milk in Tris-buffered saline (TBS) and immunoblotting was carried out with specific 
antibodies diluted in 1 % BSA. After the wash with TBS containing 0.05 % Tween 20 (Amersham 
Biosciences) the primary antibodies were followed by secondary antibodies and again after the 
washes the secondary antibodies coupled to horseradish peroxidase (Dako Cytomation, Denmark) 
was used. The signal was then detected with enhanced chemiluminescence ECL (Amersham Life 
Sciences or Millipore).   
 
Immunofluorescence (I, II, III) 
Monolayer cells were cultured on cover slips, washed with PBS and fixed with 3.5 % 
paraformaldehyde (PFA). Fixation was followed by permeabilization of the cells with 0.5 % NP-40 
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and blocking with 3 % BSA. The cover slips were incubated at 37 C for 45 minutes with primary 
antibodies diluted in 3 % BSA, after which they were washed with PBS. Secondary antibodies 
(conjugated Alexa fluorochromes 488 nm or 595 nm from Molecular Probes) were incubated on 
cells for 45 minutes at 37 C followed by washes with PBS. DNA was stained using DAPI 
(Molecular Probes) or Hoechst33522 and cover slips were mounted on microscopy slides. 
Rhodamine phalloidin was used to stain actin filaments (I).  
The fluorochromes were visualized by Zeiss Axioplan 2 Imaging MOT (Jena, Germany) and 
imaged with Zeiss Axiocam CCD-videocamera and AxioVision program.  
For 5BrdU-incorporation assay (I), the cells were first incubated in the presence of 5BrdU for 
indicated times followed by fixation of the cells with 3.5 % PFA and permeabilization in 1.5 M HCl 
for 20 minutes. 5BrdU-labeling was then detected using anti-5BrdU- antibody (Amersham) and 
fluorescent secondary antibodies.  
 
Northern blotting (I) 
Total RNA was purified from the cells by using RNeasy kit (Qiagen, Valencia, CA). Extracted 
RNA was separated in 1 % agarose gels containing formaldehyde followed by a transfer to the 
nylon membrane (Hybond-N+, Amersham) using 20x standard sodium citrate (SSC). cDNA insert 
was probed with α-32P dCTP by random priming (Ready-To-Go, Pharmacia) using ExpressHyb 
solution (Clontech). Autoradiograms were exposed on film and quantitated by Fujifilm BAS-2500 
Image Analyzer. RNA levels were normalized against 18 S RNA.  
 
Flow cytometry (I) 
Cells were trypsinized, and either fixed in 3.5 % PFA or in 70 % cold ethanol followed by washes 
with PBS. Cells were then permeabilized with 0.5% NP-40 in PBS and incubated with indicated 
antibodies diluted in 1% BSA containing 0.1% Tween-20. After washes primary antibodies were 
conjugated with secondary antibodies by using fluorescent Alexa-488 (Molecular Probes). DNA 
was stained with propidium iodide (Molecular Probes) or with DAPI. Analysis of the cells was 
carried out with LSR flow cytometer and Cell Quest program (Becton Dickinson, Franklin Lakes, 
NJ).   
 
Immunohistochemistry (II, III) 
Paraffin embedded tissue sections were deparaffinized using xylene and rehydrated in decreasing 
percentages of alcohol. Antigens were retrieved by heating the samples in citrate buffer for 20 
minutes (pH 6.0). Endogenous peroxidase activity was blocked with 0.3 % hydrogen peroxidase 
and Vectastain Elite ABC kit was used (Vector Laboratories) for immunohistochemistry. Primary 
antibodies were incubated on the samples overnight, and the detection was carried out using 
biotinylated antibodies, horseradish peroxisidase complex and AEC chromogen. The nuclei were 
stained using Mayers’ hematoxylin and mounted on glass slides. The control sections were treated 
with goat IgG to rule out unspecific staining. 
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Quantitative PCR (III) 
Quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR) was used to 
study the transcriptional regulation of CRP1 by TGF. For this purpose, total RNA was extracted 
using Trizol isolation method and the RNA concentration was measured using Nanodrop. 1.35 g 
of RNA was used for reverse transcription reaction performed with First-strand Super Script kit 
(Invitrogen). Each sample was used as a triplicate to perform qPCR reaction using SYBR GREEN I 
master mix (Atila Biosystem, Mountain View, CA). qPCR (ABI PRISM 7900HT) used in this study 
was from Applied Biosystems, Foster City, CA. 
 
Collagen contractility (III) 
Collagen contractility was used to study the ability of the cells to contract and the role of CRP1 in 
this event. The cells were trypsinized and counted. Type I rat tail collagen (2.2 mg/ml in 0.6% 
acetic acid) was mixed with concentrated medium (10x DMEM, L-glutamine and sodium 
bicarbonate 7.5%) and the pH of the mixture was neutralized with sterile 1 M NaOH. 50,000 WS1 
cells were resuspended in FCS, and the cells were plated inside the collagen latice on 24-well plate. 
After polymerization DMEM containing 10 % FCS was added on the wells, and the gels were 
released from the edges. After 24 hours, the diameter of the contracted gels was measured.   
 
Transfection (I, II, III) 
Several methods to transfect the cells have used in the study. For electroporation cells were first 
trypsinized, suspended in Optimem, mixed with DNA and then electropulsed with Gene Pulser II 
(Bio-Rad Laboratories, Inc., Hercules, CA). Commercial transfection kits were used according to 
the manufacturers protocol: JetPEI (Polyplus-transfection Inc. New York, NY), Lipofectamine 
(Invitrogene) and Fugene HD (Roche). 
 
Measurement of the metabolic activity (I) 
Cells were first transfected with indicated plasmids, and 48 hours post transfection, cells were 
trypsinized and replated in similar densities. Metabolic activity was measured using WST-1 cell 
proliferation assay (Roche) according to the manufacturers protocol. Absorbance was determined 
by Titertek Multiskan at 450 nm using 690 nm as a reference. 
 
Silencing by using lentiviral shRNA vectors (I, III) 
To silence CRP1 by lentiviral transduction using shRNA vectors, 293T cells were first transfected 
with gag, pol, env coding plasmids plp1, plp2 and plp-VSVG, respectively either with scrambled 
vector cloned in pDSL_phUGIH or CRP1 targeting shRNA cloned in pDSL_phUGIH. Cells were 
incubated for two days followed by collection of the medium containing the virus particles. Cells 
were then transduced with the viral supernatant in the presence of polybrene overnight and 




siRNA oligos against Smad2 (#4392420) and negative control (# 4390843) were from Ambion 
(Austin, TX), and were transfected to the cells using Lipofectamine RNAiMAX (Invitrogen) 




RESULTS AND DISCUSSION 
 
LOCALIZATION OF CRP1 TO THE ACTIN CYTOSKELETON (I, III) 
To get overview of the function of CRP1 in the cell, we studied its localization. Like several other 
LIM domain proteins, CRP1 also localizes to actin-rich structures such as focal adhesions, actin 
stress fibers, protrusion, cleavage furrow and midbody (Fig. 8A, 9A).  
CRP1 localizes to stress fibers (Fig. 8A), and in myofibroblasts it also co-localizes with SMA 
(III). Stress fibers may display a periodical staining pattern, as is the case with α-actinin and myosin 
II (Naumanen et al., 2008), but CRP1 localizes along the whole stress fiber (Fig. 8). WLIM1 
(tobacco) (Thomas et al., 2007b) and hhLIM (human heart LIM) (Zheng et al., 2008) are examples 
of LIM domain proteins that are able to bind actin and bundle stress fibers. Also CRP1 has been 
shown to bundle monomeric actin into filamentous form and ectopic expression to result in thicker 
actin bundles (Tran et al., 2005). Our unpublished data supports the observation that ectopic 
expression of CRP1 promotes the formation of thicker actin stress fibers.  
Latrunculin A is a chemical that disrupts the actin cytoskeleton by sequestering monomeric actin 
and preventing its polymerization. CRP2 has the ability to bind both G and F forms of actin, and to 
localize to stress fibers in differentiating smooth muscle cells and to nucleus in response to actin 
cytoskeleton disruption (Kihara et al., 2011). Furthermore, overexpression of WLIM1 delayed the 
actin depolymerization by latrunculin B by promoting the bundling (Thomas et al., 2006). In our 
studies, latrunculin A increased the levels of CRP1 in 4 hours, suggesting that CRP1 also responds 
to disruption of the actin cytoskeleton (Fig. 8B). This implicates that it may be needed to stabilize 
the actin stress fibers or to delay the disruption similarly to WLIM1. The ratio of G actin/ F actin 
affects the activation of SRF, and the monomeric actin retains its coactivator MAL in cytoplasm 
(Miralles et al. 2003). As CRP1 is transcriptionally regulated by SRF (Lilly et al. 2001), but is not a 
target of MAL (Selvaraj & Prywes, 2004), the increase of CRP1 by latrunculin A is probably not 
mediated by SRF-MAL pathway, but the increase may rather be the consequence of the stress 
response in actin cytoskeleton. Furthermore, inhibition of Rho effector ROCK also disrupts the 
filamentous actin. Interestingly, ROCK inhibitor (Y27632) effect on CRP1 expression level is 
opposite to the one detected with Latrunculin A, since ROCK inhibitor decreases its levels. The 
results implicate that CRP1 acts directly under regulation of Rho- pathway (Fig. 8 C).  
Like several other LIM domain- proteins, CRP3 and zyxin are also essential for actin cytoskeleton 
structure and stress fiber reorganization. CRP3 regulates the actin stress fiber depolymerization in a 
complex with cofilin (Papalouka et al., 2009), and CRP3 deficient mice display disrupted 
cytoskeleton (Arber et al., 1997). Moreover, zyxin is required for actin stress fiber formation 
(Hoffman et al., 2006) and also during TGFβ- induced EMT (Mori et al., 2009). However, murine 
Csrp1 knock out smooth muscle cells did not show any detectable changes in actin cytoskeleton 
organization (Lilly et al. 2010). This was further supported by our own data by using CRP1 
silencing and actin cytoskeleton staining (unpublished data).  
Focal adhesions are structures that are required for cell attachment to the surface, and provide a link 
between actin cytoskeleton and the extracellular matrix. Cell adhesion is also a required for cell 
growth, since cells do not grow in anchorage independent manner. CRP1 localizes to focal 
adhesions and interacts with α-actinin (Pomies et al., 1997) and zyxin (Sadler et al., 1992), which 
can both be found from focal adhesions as well. The formation and maturation of focal adhesions 
involves significant changes in protein composition and requires acto-myosin contractility. Two 
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recent studies have enlightened the composition of the focal adhesion proteome and revealed 
differences in it after inhibition of myosin II which is needed for maturation of focal adhesions 
(Schiller et al., 2011; Kuo et al., 2011). Interestingly, LIM domain proteins were represented as a 
large group of proteins lost from focal adhesions in response to inhibition of myosin II activity 
(Schiller et al., 2011). CRP1 was identified in both studies as one of them suggesting that several 
LIM domain proteins, like CRP1, are recruited to focal adhesions in response actomyosin 
contractility.  
Lamellipodias and protrusions are actin-rich structure in the mobile edge of the cell. Several LIM 
domain proteins are known to regulate cell migration and spreading, including LASP-1 (Raman et 
al., 2010), PINCH1 (Ito et al., 2010), PINCH2 (Zhang et al., 2002), zyxin (Mori et al., 2009), CRP2 
(Lin et al., 2008) and FHL3 (Coghill et al., 2003). As CRP1 is strongly localized in protrusions of 
the cell, it is intriguing to speculate that CRP1 could either function in cell migration or 
polarization. Furthermore, in a zebrafish model Csrp1 was identified as a regulator of dynamic cell 
movements of the mesendoderm and cardiac during morphogenesis of tissues and organs (Miyasaka 
et al., 2007). However, we found no clear evidence for its function in migration in human epithelial 
or fibroblast cells (unpublished results). It is possible that CRP1 is only required for cell migration 
during embryonal development or that the discrepancy between the results is due to the cell or 






Figure 8. CRP1 localizes to actin rich-structures, and is regulated by actin cytoskeleton disrupting chemicals. Human 
lung adenocarcinoma cells (A549) were stained for CRP1 (green), actin cytoskeleton (rhodamine phalloidin, red) and 
nuclei (DAPI, blue) and imaged using fluorescent microscopy (A). Normal human skin fibroblasts were treated with 
latrunculin A and cells were lysed 4 hours post treatment. Western analysis of CRP1 is shown. GADPH used as a 
loading control (B). A549 cells were treated with ROCK inhibitor (Y27632) for 24 hours. Western analysis was 
performed as in B (C). 
 
EFFECTS OF CRP1 ON CELL PROLIFERATION (I, unpublished data) 
Already in early studies, CRP1 was noticed to be decreased under starvation in resting cells, and to 
be rapidly induced in response to serum addition. Furthermore, it was also downregulated in 
transformed cells (Wang et al., 1992).  
When Csrp1 was identified as a UVC-induced gene in microarray study, it was chosen due to its 
potential impact on cell growth and differentiation. During the course of our studies we have 
collected evidence that CRP1 affects the cell growth. Our attempts to generate ectopic CRP1 
expressing cell clones turned out to be difficult, since overexpression of CRP1 was not achieved 
despite repeated attempts. Only 2 mouse fibroblast (NIH3T3) cell clones transfected with Myc 
tagged CRP1 out of 21 expressed CRP1 at a very weak level. The level of CRP1 was increased by 
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treating the cells with proteosome inhibitor, MG132, implicating that excess amount of CRP1 was 
constantly degraded (unpublished observations).  
Ectopic Myc-CRP1 suppressed cell proliferation based on 5-BrdU analysis (I). Ectopic expression 
of CRP1 also suppressed cell proliferation of human fibroblasts (WS1) as determined by cell 
counting experiments (I). Furthermore, CRP1 levels were increased by cell confluency (I), but later 
on dramatically decreased, when the cells were withdrawn from cell cycle. It is possible that CRP1 
is involved in signaling which is needed to stop the cells from multiplication in response to cell 
confluency. 
We have observed that CRP1 is increased in mitotic cells (Fig. 9A). Because changes in protein 
levels may be challenging to determine in mitotic cells under the microscope, we wanted to verify 
these results using western blotting. For that purpose we used nocodazole to inhibit microtubule 
polymerization and to arrest the cells in G2 phase. We detected stabilization of CRP1 after 
nocodazole treatment, suggesting that CRP1 is indeed increased in cells undergoing mitosis (Fig. 
9B).  
CRP1 is localized in the actin-rich midbody, which is needed during the last phase of cell division 
when the parental cell divides into two daughter cells (Fig. 9A). Several actin-associated and LIM 
domain proteins are localized in cleavage furrow/midbody region including CRP1 binding partners 
zyxin (Hirota et al., 2000) and α-actinin (Mukhina et al., 2007), which have both been reported to 
be required for proper cytokinesis. Both of these proteins localized to the cleavage furrow, and 
silencing/ overexpression of these proteins lead to a failure in cytokinesis. Zyxin was reported to 
function through interaction with tumor suppressor hwarts/ LATS1 (Hirota et al., 2000). Although 
several other LIM domain proteins are also localized in midbody and cleavage furrow, and interfere 
with cytokinesis causing mitotic defects such as bi- or multinucleated cells, we did not detect 
apparent distinct phenotype changes of mitotic Csrp1 knock down cells (unpublished data). 
However, it is possible that CRP1 reduces cell proliferation and delays cell cycle progression, 





Figure 9. CRP1 localizes to midbody and cleavage furrow, and its levels are increased in G2/M arrested cells. Human 
lung adenocarcinoma cells (A549) were stained for CRP1 (green), actin (red) and nuclei (DAPI, blue) and imaged using 
fluorescent microscopy (A). A549 and human cervical cancer cells (Hela) were treated with nocodazole for 24 hours 
and CRP1 and phosphorylated histone 3 (mitosis marker) were detected in western blotting. GAPDH was used as a 
loading control. 
 
REGULATION OF CRP1 BY UV RADIATION (I, II) 
Csrp1 gene was induced by UVC in a microarray study performed in our lab (Gentile et al., 2003) 
aiming at identification of UVC regulated genes in WS1 cells. The cells were treated either with 
low (10 J/m2) or high (50 J/m2) dose of UVC for 6, 12, 18, 24 hours. Csrp1 underwent sustained 
transcriptional induction by high dose with all time points after UVR, and transient transcriptional 
induction by a low dose. As a cellular response, the low dose induces a transient cell cycle arrest 
and high dose induces apoptosis (Gentile et al., 2003). Assuming that highly stressed cells would 
most probably not consume energy on producing transcripts with no relevance, we studied the 
function of CRP1 in UVC-induced cell stress. We showed using several methods that CRP1 
provides a survival advantage in response to UVC. Cells expressing ectopic CRP1 supported 
cellular attachment and metabolic activity and were less apoptotic after UVC irradiation and 
staurosporine treated cells. Furthermore, silencing of CRP1 resulted in increased cell death in 
irradiated and staurosporine treated cells (I). 
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Keratinocytes comprise the majority of the cells in the skin that are exposed to solar radiation. 
Given that the microarray study was performed in normal human fibroblasts, and Csrp1 induction 
by UVC was verified in the same cells, we wanted to study the UV responsiveness of CRP1 in 
keratinocytes with physiologically relevant doses and wavelength (UVB). We found that CRP1 was 
induced by UVB in normal human epithelial keratinocytes (NHEK), but the induction was impaired 
in transformed keratinocytes (HaCaT, A431) (II). Out of several cancer cell lines tested, only A549 
cells show induction of CRP1 in response to UV irradiation. We observed that the expression of 
CRP1 was affected by cell growth conditions, and that the induction of CRP1 did not occur unless 
the cells were in the actively growing phase (I). It seems possible that some UVC-regulated 
pathways are impaired or not functional in transformed keratinocytes and CRP1 is mainly regulated 
by UV in normal untransformed cells. Furthermore, we found that CRP1 was cleaved as a caspase-
dependent manner during the UVB-induced apoptosis. This may suggest general protein 
degradation, or that the cleavage products have more special functions (II). 
Although UVR causes DNA damage and UVC largely models pure DNA damage, we found no 
evidence that CRP1 would be directly induced by DNA damage itself. The primary types of UVR 
induced DNA damage are CPDs and pyrimidine dimers. These are mimicked by 4-nitroquinoline 1-
oxide (4NQO), which was used to treat the cells. However, 4NQO did not increase the levels of 
CRP1 (unpublished data). Furthermore, ionizing radiation mainly causes double strand breaks in 
DNA, but did not increase the levels of CRP1 either (I). Since UVR causes other types of damage in 
the cell, like disruption of the actin cytoskeleton, we hypothesize that this may be one possible 
explanation of CRP1 induction by UVR. Interestingly, CRP1 has been proposed to act as an actin 
cytoskeleton bundling factor (Tran et al., 2005) and we have seen that CRP1 is enhanced by 
latrunculin A, which disrupts the actin cytoskeleton by inhibiting actin polymerization (Fig. 8B). 
Therefore, it is possible that one way to promote cell survival in response to UVR is to induce the 
expression of CRP1 in order to maintain cell morphology by stabilizing the structure of actin 
cytoskeleton.   
Interestingly, CRP1 was increased by UVC in human skin fibroblasts (I), but not in primary human 
keratinocytes (II). On the other hand, CRP1 was increased by UVB in NHEK (II), but not in WS1 
cells (II). UVA slightly increased the levels (1.5) of CRP1 in NHEK. MAPK genes are an example 
of genes, whose induction by UVR is highly dependent on wavelength, doses and cell lines used 
(Bode and Dong, 2003). The induction of CRP1 by UVR also seems to vary by different 
wavelengths, cell types used and doses.  
In addition to CRP1, several other LIM domain proteins are also regulated by UV-treatment 
including zyxin, RIL, FHL2 and enigma. Although zyxin, the interacting protein partner of CRP1, 
was phosphorylated in response to UVC-irradiation and translocated into nucleus (Hervy et al., 
2010), no phosphorylation nor localization changes of CRP1 was detected. Several LIM domain 
proteins have been shown to participate in cell fate decision between survival and apoptosis, 
although the effects differ from one another. Similarly to the finding that CRP1 promoted cell 
survival in response to UVR and staurosporine treatment, enigma also promoted tumor cell survival 
in mice by suppressing p53 dependent apoptosis (Jung et al., 2010). FHL2 accumulated in the 
nucleus after UV-irradiation, where it was bound to E4F1 and negatively regulated its ability to 
inhibit cell proliferation (Paul et al., 2006). However, also cell death promoting LIM domain 
proteins exists, like zyxin, which promotes apoptosis by interacting with CARP-1 (Hervy et al., 
2010) and RIL, which sensitizes cells to apoptosis in response to UVR (Boumber et al., 2007).  
LIM domain proteins modulate signal transduction pathways, such as PKC and TGF. PKCs are 
serine threonine kinases that participate in several signal transduction pathways and are activated 
upon signals, such as Ca2+ or diacylglycerol. PKC has been found to interact with LIM domains of 
several different LIM domain proteins (Kuroda et al., 1996). Enigma homolog (ENH1) interacts 
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with N-terminus of PKC1 via its LIM domains, translocates PKC1 from cytoplasm to plasma 
membrane and activates it. LIM domain proteins cypher1 and enigma operated similarly, whereas 
many other LIM domain proteins were able to interact, but not to activate PKC1. NH1 activated 
PKC in isoform dependent manner; increasing the activation of PKC and PKC, and decreasing 
the activity of PKC (Maturana et al., 2011). We found that PKC pathway mediates the induction 
of CRP1 by UVC (I). CRP1 was one of the interacting LIM domain proteins, although not capable 
of activation (Kuroda et al., 1996). We also showed that staurosporine, which is a PKC inhibitor 
and a potent apoptosis inducer, increased the expression of CRP1 (I). The increase in CRP1 by 
staurosporine was posttranscriptional. Further experimentation would be needed to resolve whether 
apoptosis or PKC pathway inhibition trigger CRP1 protein increases in the cell.  
 
CRP1 IN SKIN DISEASES (II) 
Given that solar exposure primarily affects the skin and causes skin diseases, we studied CRP1 
expression in normal and in sun exposed human skin. CRP1 was found expressed in several normal 
skin structures such as smooth muscle cells, vasculature, hair root sheat, sebaceous gland and sweat 
gland. However, very little CRP1 was expressed in normal keratinocytes (II).  
We also studied the expression of CRP1 in AK and SCC. We analyzed four AK human skin 
samples, and found that three out of four samples had epidermal expression of CRP1 in basal 
keratinocytes in dysplastic area (II). On the other hand CRP1 was not expressed in transformed cells 
in SCC, but was expressed in cancer-associated myofibroblasts surrounding the tumor area in 2 out 
of 4 samples. These findings were further supported by publicly available microarray-data, which 
suggested that Csrp1 expression was increased in AK, and decreased in SCC. The results suggest 
that UVR also induces CRP1 in keratinocytes as the levels of CRP1 are increased in AK skin 
sections. It is also possible that CRP1 participates in the survival of damaged keratinocytes, 
therefore promoting the formation of the disease. Interestingly, differences in expression of death 
receptors (FAS and TRAIL receptor) between non-irradiated, AK and SCC skin have observed (Erb 
et al., 2005). Apoptotic pathways are commonly dysfunctional in cancers, and the expression of 
death receptor expression is present in AK, but absent in SCC. Because our data showed that CRP1 
may act as an anti-apoptotic factor upon UVR and staurosporine induced apoptosis, it is possible 
that in AK CRP1 expression is high because of still functional apoptotic pathways, but impaired 
apoptosis pathways in SCC do not support the expression of CRP1 even in the presence of cellular 
damage.  
Furthermore, several LIM domain proteins affect cell growth and are involved in tumorigenesis. 
Interestingly, Csrp1 has also been found aberrantly methylated, and subsequently downregulated, in 
approximately half of hepatocellular carcinomas (Hirasawa et al., 2006). EPLIN (epithelial protein 
lost in neoplasm) is another LIM domain protein that is frequently silenced in several carcinomas, 
including SCC of head and neck cancers. Depletion of EPLIN enhanced EMT, proliferation, 
migration and invasion, and its downregulation correlated with metastases of prostate, breast, colon 
and head and neck SCC (Zhang et al., 2011). We did not find CRP1 to be required for EMT (III) or 
migration (unpublished data), but given that we observed using several approaches that CRP1 
inhibits cell proliferation, the silencing of CRP1 might be advantageous in some cases to promote 
the tumor characteristics. Whether CRP1 is downregulated in other carcinomas as well, and for 
what reason would that be beneficial for the tumors, remains to be determined. 
 
REGULATION OF CRP1 BY TGF SIGNALING PATHWAY (III) 
We have shown that CRP1 is expressed at higher levels in myofibroblasts than in human skin 
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fibroblasts, suggesting that its levels may be regulated by the differentiation status of the cells (I, II, 
III). Given that TGF causes the transdifferentiation of myofibroblasts and regulates several LIM 
domain proteins, we studied the levels and regulation of CRP1 by TGF1.  
We found that TGF1 upregulated CRP1 at protein level in biphasic appearing manner. We treated 
the cells with two different TGF concentrations, 3 and 5 ng /ml, and observed that although 
magnitude in increase of CRP1 was similar, the increase was more rapid with the higher 
concentration (5ng/ml) (III). CRP1 levels increased 4 hours after TGF-treatment using the lower 
concentration, and already within 1 hour using the higher concentration. The increase in CRP1 was 
sustained for several days.  
Interestingly, both low and high doses of TGF cause rapid transient (15-45 min) increase in the 
levels of CRP1, parallel to SMAD2/3 phosphorylation. Using the low dose of TGF, the increase in 
CRP1 was consistenly diminished around one hour, whereas this decrease was less prominent using 
the higher dose, possibly because the sustained increase of CRP1 started approximately at this time. 
The biphasic response was abrogated when the cells were incubated with an inhibitor of 
proteasomal activity (MG132), suggesting that the increased levels of CRP1 are actively degraded 
by proteasome (III).  
Sustained induction was blocked with the treatment with SMAD3 phosphorylation inhibitor and 
using TGF1 type I receptor inhibitor (SB431542) (III). Given that Csrp1 mRNA levels were 
largely unaffected following TGF treatment, the increase of CRP1 seemed to be independent of 
TGF1-induced transcriptional regulation. Regulation of CRP1 on protein level was further 
supported by observation that ectopic CRP1 is also stabilized by TGF. The kinetics of induction of 
CRP2 by TGF1 are similar, as CRP2 protein were increased after two hours of TGF1 peaking at 
24 hours post treatment (Lin et al., 2008), and CRP2 induction was also dependent on type I 
receptor (Herrmann et al., 2006). However, in contrast to CRP1, CRP2 is regulated by TGF1 at a 
transcriptional level (Lin et al., 2008).  
Although the sustained increase of CRP1 appeared dependent on type I receptor and activated 
Smad-pathway, the rapid induction was independent of both (III). However, these pathways are not 
fully differently regulated, as both are dependent on p38 signaling pathway (Fig. 10). Interestingly, 
p38/MAPKs have been reported to mediate the signaling from TGF receptor III independently of 
Smads (Margulis et al. 2008). Furthermore, p38 MAPK has been shown to mediate TGF- 
regulated apoptosis and EMT independently of Smads (Yu et al., 2002), and p38 MAPK pathway is 
activated by TGF- type III receptor (betaglycan) (Santander et al., 2006; You et al., 2007). Given 
that the type I receptor inhibitor used here was without effect on the rapid response, it is possible 




Figure 10. CRP1 is regulated by TGF in biphasic-appearing manner. Rapid increase of CRP1 occurs within one hour 
and is independent on receptor I-mediated signaling, but dependent on p38/MAPK pathway. Sustained induction of 
CRP1 by TGF is dependent on receptor I-mediated signaling and p38-mediated signaling. CRP1 increase does not 
occur at transcriptional level.    
 
Furthermore, dyxin is another LIM domain protein that is regulated by p38/ MAPKs. Dyxin may 
participate in regulating hypertrophic process, since the expression of dyxin was rapidly 
upregulated in response to mechanical load, and this increase being at least partially mediated by 
p38 MAPK (Luosujarvi et al., 2010). 
LIM domain proteins modulate TGF-signaling pathway. Hic-5/ARA55 (Wang et al., 2005, Wang 
et al., 2008) and FHL proteins (Ding et al., 2009) interact with Smads. Given that the sustained 
increase of CRP1 by TGF was dependent on Smad-signaling and that the rapid induction 
paralleled Smad phosphorylation, we tested whether CRP1 could interact with Smad3 or Smad7. 
However, no interaction between CRP1 and Smad3 or Smad7 was detected (III). We were also 
interested whether CRP1 participates in the phosphorylation of Smads. However, we could find no 
evidence supporting this (III).  
    
CRP1 IN MYOFIBROBLAST DIFFERENTIATION (I, II, III) AND IN CONTRACTILITY (III) 
Given the wide variety of different functions of TGF and that several LIM domain proteins are 
involved in TGF-pathway, we tested whether CRP1 mediates TGF-regulated functions. We 
noticed that CRP1 levels were elevated in normal human skin fibroblasts co-expressing -SMA. 
TGF regulates the expression of -SMA, and induces myofibroblast differentiation. Since CRP1 
has previously been shown to regulate -SMA expression together with SRF and GATA6 (Chang 
et al., 2003), and is regulated by TGF (III), we tested whether CRP1 regulates myofibroblast 
differentiation. We expressed CRP1 in NIH3T3, and double-stained the cells for FLAG-CRP1 and 
-SMA. Ectopic CRP1 could not induce -SMA expression in the cells (III). Because CRP1, at 
least alone, could not induce myofibroblast differentiation, we also tested whether it acts as a 
limiting factor. However, silencing of CRP1 in WS1 cells confirmed our results that CRP1 did not 
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affect myofibroblast differentiation (unpublished data, III). This observation was further supported 
by a mouse knock out study, which it showed that CRP1 is not required for -SMA expression in 
the absence or presence of TGF (Lilly et al., 2010).  
TGF promotes EMT, and myofibroblasts can originate from epithelial cells as suggested regarding 
IPF. Moreover, LIM domain proteins EPLIN (Zhang et al., 2011) and zyxin (Mori et al., 2009) 
negatively and positively, respectively, regulate EMT. Given that CRP1 is associated with 
myofibroblasts and localizes to actin cytoskeleton, we studied whether CRP1 has a role in EMT. 
We silenced CRP1 in A549 cells, and treated the cells with TGF for 48 hours. However, silencing 
of CRP1 did not seem to have an impact on EMT markers (III). 
RhoA is one of RhoGTPases that regulates actin cytoskeleton by inducing the formation of actin 
stress fibers and cell contractility. Inhibition of ROCK significantly reduced the endogenous basal 
levels of CRP1, implicating that CRP1 is at least partially under regulation of RhoA pathway (Fig. 
8C). Since RhoA pathway also mediates TGF- signaling independently of Smads, we also tested 
whether RhoA mediates the CRP1 increase by TGF. CRP1 levels were elevated by TGF even in 
the presence of ROCK inhibitor indicating that RhoA pathway is not needed for CRP1 increase 
(Fig. 8C). Furthermore, we found that CRP1 was localized to SMA positive stress fibers needed 
for contraction (III). In addition to CRP1, other LIM domain proteins, such as EPLINα (Chen et al., 
2000), LMO7 (Hu et al., 2011) and LIMK 1/2 (Bernard, 2007), are also regulated by RhoA.  
Given that cell contractility is a distinct feature of myofibroblasts, and that CRP1 is associated with 
actin cytoskeleton and myofibroblasts, we studied whether CRP1 is needed for cell contraction. Our 
data using CRP1 silencing showed that CRP1 was needed for the contractility of the fibroblasts 
(III). In contrast to our results, Csrp1 knock out smooth muscle cells did not show difference in 
contractility as compared to the wild type cells (Lilly et al., 2010). Difference between the results 
may be due to the difference in cell type used or difference in method used.   
 
CRP1 IN IDIOPATHIC PULMONARY FIBROSIS (III) AND IN CANCER- ASSOCIATED 
FIBROBLASTS (II) 
Injury in alveolar epithelial cells together with TGF may cause the accumulation of myofibroblasts 
in the lung and promote the formation of fibrosis. Because CRP1 is expressed at higher level in 
myofibroblasts, we studied the expression of CRP1 in normal human and in IPF lungs in vivo. No 
expression of CRP1 was detected in normal alveolar epithelial cells, whereas strong expression of 
CRP1 was observed in fibroblastic foci in IPF patient lungs (III). The expression of CRP1 co-
localized with SMA in the fibroblastic foci. A significant difference in CRP1 expression between 
control and IPF patients was detected (lung tissues derived from normal (n = 5) and IPF (n = 10)) 
(III). Given that CRP1 expression levels are increased in IPF, and TGF is one of the factors 
promoting the formation of IPF, it is possible that CRP1 is elevated due to the increased production 
of TGF.  
Smad and p38/MAPK have also a role in IPF, which may implicate that CRP1 increase is mediated 
via these pathways. Several studies have shown that myofibroblasts in IPF disease may have 
transdifferentiated from alveolar epithelial cells through EMT (Willis et al. 2005). Both canonical 
and non-canonical TGF--induced pathways are involved in EMT in pulmonary epithelial cells, 
although they exhibit differential roles during it (Kolosova et al., 2011). Smad2/3 are needed for 
collagen production during EMT, but not for loss of E-cadherin or typical morphological changes 
seen upon EMT. However, p38 MAPK is required for morphological and actin cytoskeleton 
changes during EMT (Kolosova et al., 2011). MAP kinase pathways, including p38, are elevated in 
IPF patient lung samples (Yoshida et al., 2002) and p38 kinase substrate MK2 is involved in TGF- 
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induction -SMA expression and in myofibroblast differentiation (Sousa et al., 2007). Interestingly, 
p38 inhibitor (Esbriet) was recently approved for treatment of IPF in Europe (Moran, 2011). 
Other LIM-domain proteins have also been identified in fibrosis given that CRP2 levels were also 
increased in activated hepatic stellate cells, when they were transdifferentiating into myofibroblasts 
(Weiskirchen et al., 2001). CRP2 was also induced during liver fibrogenesis (Herrmann et al., 
2006). Furthermore, PINCH 1 and 2 double knock-out mice exhibited severe dilated 
cardiomyopathy and died of heart failure within 4 weeks. Mutated cardiomyocytes were 
significantly altered and suffered from abnormal adhesion, cell growth, and cell death. Ventricules 
were thinner and fibrotic causing heart failure (Liang et al., 2009) suggesting PINCH proteins may 
also play a role in fibrotic processes.  
Interestingly, several LIM-domain proteins, including FHL2, PINCH and CRP1, have been found 
expressed in CAFs surrounding the tumour tissue. FHL2 was found co-expressed with αSMA in 
myofibroblasts of the tumour invasive front in sporadic colon and in hereditary non-polyposis 
colon-rectal cancers. In fibroblasts FHL2 expression was regulated by TGF- signalling pathway, 
and required for TGF- induced migration. The results implicated that tumour-derived TGF via 
FHL2 induces the migration of the peritumoural fibroblasts and increases the tight connection 
between tumour cells and myofibroblasts (Gullotti et al., 2011). Furthermore, the expression of 
PINCH was increased in stroma of normal mucosa, to colorectal adenocarcinoma to metastasis and 
is higher in invasive front than in intratumoural stroma. Expression of PINCH is primarily seen in 
fibroblasts, myofibroblasts and proportion of endothelial cells and correlates with worse prognosis, 
implicating that PINCH may affect the tumour-stroma association promoting progression of the 
tumour (Gao et al., 2004). CRP1 was also found expressed in CAFs in cutaneous squamous cell 
carcinoma (II). Interestingly, CAFs have been reported to add to the tumorigenic potential of 
epidermal cells of SCC in a study that compared the properties of normal dermal fibroblasts to 
CAFs (Commandeur et al., 2011). CAFs decreased the proliferation and differentiation of the 
epidermal cells, and further increased the invasive potential and dermal-epidermal detachment of 
two SCC cell lines, implicating that CAFs play an important role during the formation of SCC 
(Commandeur et al., 2011).  
Suprisingly, all the LIM-domain proteins associated with fibrotic myofibroblasts and CAFs can be 
categorized into LIM-only proteins. Whether the structural and functional similarity of these 
proteins actually plays a role in formation of fibrosis and whether they have the capacity to 
transform the normal fibroblasts into CAFs remain to be seen. Moreover, the exact role of CRP1 in 
fibrosis formation and in transformation of normal fibroblasts to CAFs remains to be answered in 




Ultraviolet radiation (UVR) is one of the major environmental genotoxic carcinogens that cause 
DNA lesions. UVR induced damage in the cell contributes to formation of all types of skin cancers 
including basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (SCC) and cutaneous 
melanoma. It has been estimated that 2-3 million new cases of BCC and SCC occur worldwide each 
year (Narayanan et al., 2010). The original aim of this study was to identify and functionally 
chracterize novel UVR regulated genes based on a microarray study detailing UV-regulated 
transcriptome. 
LIM domain proteins are involved in multiple functions in cell including cell growth, damage 
signalling, cell fate determination and signal transduction. We studied the regulation and function of 
LIM domain protein, cysteine rich protein 1 (CRP1) upon UV irradiation and found Csrp1 induced 
by UVC in normal human skin fibroblasts with lethal dose. CRP1 was also increased in normal 
human keratinocytes by UVB. Furthermore, we find that CRP1 is cleaved in caspase-dependent 
manner prior to UVB-induced apoptosis and provides a survival advantage for the cells when 
ectopically expressed by decreasing cellular death and increasing cellular metabolic activity and 
attachment. Silencing of CRP1 predisposed the cells to apoptosis. Actinic keratosis (AK) is a 
disease associated with excess expose to sunlight and to sunburn, and may lead to cutaneous 
squamous cell carcinoma (SCC). We studied the levels of CRP1 in normal, AK and SCC samples. 
Very little expression of CRP1 was detected in normal keratinocytes whereas CRP1 levels were 
increased in basal keratinocytes in AK. In SCC, CRP1 was only expressed in cancer-associated 
fibroblasts. These results implicate that CRP1 is increased in keratinocytes in response to excess 
exposure to sunlight and may protect the cells from sunburn induced apoptosis. However, the role 
of CRP1 in AK and SCC lesions needs further validation.     
CRP1 is affected by cellular growth conditions, as the UV-induction was only detected in actively 
growing normal, untransformed cells. Furthermore, CRP1 levels increase by proliferation 
suppressing signals such as cell confluency, apoptosis inducing staurosporine-treatment and it also 
suppresses the cell proliferation. The function and mechanism of how CRP1 affects the cell 
proliferation still remains unclear and needs further experimentation.     
CRP1 was also found to be regulated by TGF in biphasic appearing manner. TGF treatment 
caused first rapid increase in CRP1 which was then diminished within an hour and later sustained 
increase in CRP1 which lasts for several days. Elevation occurred in transcription independent 
manner via Smad and non-Smad signaling pathways. The regulation of CRP1 by TGF was 
associated with myofibroblast differentiation and fibrosis, and CRP1 expression was significantly 
increased in idiopathic pulmonary fibrosis (IPF) specimens as compared to the normal lung. CRP1 
was also required for cell contractility. However, the function of CRP1 in TGF signaling needs 
further exploration. 
As a conclusion, we have studied LIM domain protein CRP1 in UVR induced cell stress and in cell 
proliferation. We find CRP1 as a growth suppressive protein regulated by UVR which protects the 
cells against UVR-induced cell death. Furthermore, we find CRP1 levels elevated in sunlight 
exposed keratinocytes in AK samples. CRP1 was also found regulated by TGF via Smad and non-
Smad pathways and to be significantly elevated in idiopathic pulmonary fibrosis.  
These studies identify CRP1 as a stress responsive and cytokine regulated cytoskeletal protein that 
participates in pathological processes involved in fibrotic diseases and cancer.  
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